Novartis Institutes for BioMedical Research
LIK066
Clinical Trial Protocol CLIK066B2203 / [STUDY_ID_REMOVED]
A randomized, open label , two-part, three -period, 
cross -over study
 to inv estigate the effects of carbohy drate 
in diet and to evaluate supplements on the gastrointestinal 
tolerability of LIK066 in ov erweight or obese subjects
Document type: Amended Protocol Version
EUDRACT number: N/A
Version number: v01(Clean)
Clinical Trial Phase: II
Release date: 08-Aug-2017
Property of Novartis
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of Novartis

Novartis Confidential Page 2
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
Site Operations Manual (SOM)
A Site Operations Manual (SOM) accompanies this protocol, providing the operational details 
for study  conduct. Note: The SOM will not be part of the Clinical Study  Report.
Notification of serious adverse events
Dear Investigator,
You must report a serious adverse event (SAE) (initial or follow -up) to Novartis as 
summarized below.  Refer to Section 9.2 of the protocol for SAE criteria and additional 
requirements.  See also page 2 of the Site Operations Manual for further details on the method 
of reporting a SAE.
Complete SAE report
Submit SAE report to Novartis Drug Safet y and Epidemiology  (
DS&E) within 24 hours 
after awareness of the SAE
Notify  the Novartis Medical Lead
The fax number(s) and email address(es) are located in the Site Operations Manual. 

Novartis Confidential Page 3
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
Table of contents
Site Operations Manual (SOM)........................................................................................... 2
Notification of serious adverse events ................................................................................. 2
Table of contents ................................................................................................................. 3
List of tables ........................................................................................................................ 6
List of figures ...................................................................................................................... 6
List of abbreviations ............................................................................................................ 7
Pharmacokinetic definitions and sy mbols ......................................................................... 10
Glossary  of terms ............................................................................................................... 11
Amendment 1 (August 2017) ............................................................................................ 13
Protocol sy nopsis ............................................................................................................... 14
1Introduction ....................................................................................................................... 17
1.1 Background ............................................................................................................ 17
18
19
1.3 Clinical data ........................................................................................................... 19
1.3.1 Human safet y and tolerability  data ....................................................... 19
20
1.3.3 Human pharmacod ynamic data ............................................................. 20
1.4 Study  purpose ........................................................................................................ 21
2Study  objectives and endpoints ......................................................................................... 21
2.1 Primary  objective(s) ............................................................................................... 21
2.2 Secondary  objective(s) ........................................................................................... 21
22
3Investigational plan ........................................................................................................... 22
3.1 Study  design ........................................................................................................... 22
3.2 Rationale of study  design ....................................................................................... 28
28
3.4
Rationale for choice of comparator ....................................................................... 29
3.5 Purpose and timing 
of interim anal yses/design adaptations .................................. 30
3.6 Risks and benefits ................................ ................................ ................................ ..30
3.6.1 Blood sample volumes .......................................................................... 31
4Population .......................................................................................................................... 31
4.1 Inclusion criteria .................................................................................................... 31
4.2 Exclusion criteria ................................................................................................... 32
5Restrictions for Study  Subjects
................................ ................................ ......................... 34

Novartis Confidential Page 4
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
5.1 Contraception requirements ................................................................................... 34
5.2 Prohibited treatment ............................................................................................... 34
5.3 Dietary  restrictions and smoking ........................................................................... 35
5.4
Other restrictions ................................................................................................... 36
6Treatment ........................................................................................................................... 37
6.1 Study  treatment ...................................................................................................... 37
6.1.1 Investigational treatment and control drugs .......................................... 37
6.1.2 Additional study  treatment .................................................................... 37
6.2 Treatment arms ...................................................................................................... 37
6.3
Treatment assignment and randomization............................................................. 38
6.4 Treating the subject ................................................................................................ 39
6.5
Permitted dose adjustments and in terruptions of study  treatment ......................... 39
6.6 Emergency  breaking of assigned treatment code .................................................. 39
6.7 Treatment exposure and compliance ..................................................................... 39
6.8 Recommended treatment of adverse events .......................................................... 39
6.9
Rescue medication................................................................................................. 39
6.10 Concomitant treatment ........................................................................................... 40
7Study  completion and discontinuation .............................................................................. 40
7.1 Study  completion and post -study  treatment .......................................................... 40
7.2 Discontinuation of study  treatment ........................................................................ 40
7.3 Withdrawal of informed consent ........................................................................... 42
7.4 Lost to follow -
up ................................................................................................... 42
7.5 Study  Stopping rules .............................................................................................. 42
7.6 Early study termination by the sponsor ................................................................. 42
8
Procedures and assessments .............................................................................................. 43
8.1 Assessment schedule ............................................................................................. 43
8.2 Informed consent procedures
................................................................................. 52
8.3
Subject screening................................................................................................... 52
8.4
Subject demographics/other baseline characteristics............................................. 52
8.5 Efficacy  / Pharmacod ynamics ............................................................................... 53
8.5.1
Patient- Reported Outcome .................................................................... 53
8.6
Safety ..................................................................................................................... 54
8.6.1 Electrocardiogram (ECG) ..................................................................... 54
8.6.2 Vital Signs ............................................................................................. 54
8.6.3 Hematology ........................................................................................... 54
8.6.4 Physical Examination ............................................................................ 54

Novartis Confidential Page 5
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
8.6.5 Clinical Chemistry ................................................................................ 55
8.6.6 Urinal ysis.............................................................................................. 55
8.6.7 Body Height .......................................................................................... 55
8.6.8 Body Weight ......................................................................................... 55
55
56
56
9Safet y monitoring .............................................................................................................. 56
9.1 Adverse events ....................................................................................................... 56
9.2 Serious adverse event reporting ............................................................................. 58
9.2.1 Definition of SAE ................................................................................. 58
9.2.2 SAE reporting
........................................................................................ 58
9.3 Liver safety  monitoring ......................................................................................... 59
9.4 Renal safet y monitoring ......................................................................................... 60
9.5 Reporting Medication errors including misuse/abuse ........................................... 61
9.6 Pregnancy  reporting ............................................................................................... 61
9.7 Early phase safet y monitoring ............................................................................... 62
9.8 Monitoring h ypoglycemia ..................................................................................... 62
9.9 Monitoring orthostatic hy potension ....................................................................... 62
9.10
Monitoring ketoacidosis ........................................................................................ 62
10Data review and database management ................................ ................................ ............. 63
10.1 Site monitoring ...................................................................................................... 63
10.2
Data collection....................................................................................................... 63
10.3 Database management and quality  control ............................................................ 64
10.4 Data Monitoring Committee .................................................................................. 64
10.5 Adjudication Committee ........................................................................................ 64
11Data analy sis...................................................................................................................... 65
11.1 Analy sis sets .......................................................................................................... 65
11.2
Subject demographics and other baseline characteristics...................................... 65
11.3 Treatments ............................................................................................................. 65
11.4 Analy sis of the primary  variable(s) ....................................................................... 65
11.4.1 Variable(s) ............................................................................................. 65
11.4.2 Statistical model, hy pothesis, and method of analysis .......................... 65
11.4.3 Handling of missing values
/censoring/discontinuations ....................... 66
11.4.4 Sensitivity  anal yses............................................................................... 66
11.5 Analysis of secondary  variable(s) .......................................................................... 66

Novartis Confidential Page 6
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
11.5.1 Efficacy  / Pharmacod ynamics ............................................................... 66
11.5.2 Safet y
..................................................................................................... 67
11.5.3 Pharmacokinetic / pharmacod ynamic interactions ................................ 67
11.5.4 Other assessments ................................................................................. 67
68
68
69
11.7
Sample size calculation.......................................................................................... 69
11.8 Power for anal ysis of key secondary  variables ...................................................... 70
11.9 Interi m anal yses..................................................................................................... 70
12
Ethical considerations........................................................................................................ 70
12.1 Regulatory  and ethical compliance ........................................................................ 70
12.2 Responsibilities of the investigator and IRB/IEC .................................................. 70
12.3 Publication of study  protocol and results ............................................................... 71
13Protocol adherence ............................................................................................................ 71
13.1 Protocol Amendments ........................................................................................... 71
14References ................................ ................................ ................................ ......................... 72
15Appendix 1: L iver Event Definitions and Follow -up Requirements ................................. 73
16Appendix 2: Specific Renal Alert Criteria and Actions .................................................... 75
List of tables
 
20
Table 6
-1 Definition of treatment s equences ......................................................... 38
Table 6
-2 Randomization assignment numbering................................................. 38
Table 8
-1 Assessment Schedule ............................................................................ 43
Table 9
-1 Summary  of reporting requirements for medication errors................... 61
Table 15-1 Liver Event Definitions......................................................................... 73
Table 15-2 Actions required for Liver Events ................................ ......................... 74
Table 15-3 Exclusion of underly ing liver disease ................................................... 74
Table 16
-1 Specific Renal Alert Criteria and Actions ............................................. 75
Table 16
-2 Follow -up of renal events ...................................................................... 76
List of figure s
Figure 3 -
1 Part A: Effects of Carbohydrate in the Breakfast Meals....................... 26
Figure 3 -2 Part B: Effects of Supplements in the Breakfast Meals* ...................... 27

Novartis Confidential Page 7
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
List of abbreviations
AE adverse event
AESI adverse event of special interest
ALP alkaline phosphatase
ALT alanine aminotransferase
ANCOVA analysis of covariance
AST aspartate aminotransferase
BMI Body Mass Index
BUN blood urea nitrogen
CD-ROM compact disc – read onl y memory
CDS Core Data Sheet (for marketed drugs)
CFR U.S. Code of Federal Regulation
CK creatinine kinase
CO 2 carbon dioxide
COAR Clinical Operations, Analy tics & Regions
CRF Case Report/Record Form (paper or electronic)
CRO Contract Research Organization
CTC Common Toxicity  Criteria
CTRD Clinical Trial Results Database
CV coefficient of variation
DMC Data Monitoring Committee
EC Ethics committee
ECG Electrocardiogram
EDC Electronic Data Capture
ELISA Enzy me-linked immunosorbent assay
eSAE Electronic Serious Adverse Event
FDA Food and Drug Administration
GCP Good Clinical Practice
GGT Gamma -glutam yl transferase
h
hour
HIV human immunodeficiency virus

Novartis Confidential Page 8
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
i.v. intravenous
ICHInternational Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use
IEC Independent Ethics Committee
IRB Institutional Review Board
LDH lactate deh ydrogenase
LFT Liver function test
LLN lower limit of normal
LLQ lower limit of quantification
MABEL minimum anticipated biological effect level
MedDRA Medical dictionary  for regulatory  activities
mg milligram(s)
mL milliliter(s)
MRSD maximum recommended starting dose
NCDS Novartis Clinical Data Standards
o.d. once a day
p.o. oral
PA posteroanterior
PD pharmacod ynamic(s)
PK pharmacokinetic(s)
RBC red blood cell(s)
RDC Remote Data Capture
REB Research Ethics Board
s.c. subcutaneous
SAE serious adverse event
sCR serum creatinine
SD standard deviation
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic p yruvic transaminase
SOM Site Operations Manual
SUSAR Suspected Unexpected Serious Adverse Reactions
TBL total bilirubin

Novartis Confidential Page 9
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
ULN upper limit of normal
ULQ upper limit of quantification
WBC white blood cell(s)
WHO World Health Organization

Novartis Confidential Page 10
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
Pharmacokinetic definitions and sy mbols
AUClastThe area under the plasma (or serum or blood) concentration -time curve from 
time zero to the time of the last quantifiable concentration [mass x time / 
volume]
AUCtauThe area under the plasma (or serum or blood) concentration -time curve from 
time zero to the end of the dosing interval tau [mass x time / volume]
CL/FThe apparent systemic (or total body ) clearance from plasma (or serum or 
blood) following extravascular administration [volume / time]
Clast The last observed quantifiable concentration [mass / volume]
CmaxThe observed maximum plasm a (or serum or blood) concentration following 
drug administration [mass / volume]
Tlast The time point that corresponds to the last measurable concentration [time]
Tmax The time to reach the maximum concentration after drug administration [time]

Novartis Confidential Page 11
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
Glossary  of terms
Assessment A procedure used to generate data required b y the study
Cohort A specific group of subjects fulfilling certain criteria
Control drugAny drug(s) (an active drug or an inactive drug, such as a placebo) 
which is used as a compa rator to the investigational drug being tested 
in the trial
DosageDose of the study  treatment given to the subject in a time unit 
(e.g. 100mg once a day , 75 mg twice a day )
EnrollmentPoint/time of subject entry  into the study  at which informed consent
must be obtained (i.e. prior to starting any of the procedures described 
in the protocol)
EpochInterval of time in the planned conduct of a study . An epoch is 
associated with a purpose (e.g. screening, randomization, treatment, 
and follow -up) which appl ies across all arms of a study .
Investigational drugThe study  drug whose properties are being tested in the study ; this 
definition is consistent with US CFR 21 Section 312.3 and Directive 
2001/20/EC and is synony mous with “investigational new drug” or 
“test substance”
Investigational 
treatmentAll investigational drug(s) whose properties are being tested in the 
study  as well as their associated treatment controls. This includes any 
placebos, any active controls, as well as approved drugs used outside 
of their indication/approved dosage or tested in a fixed combination. 
Investigational treatment generall y does not include other treatments 
administered as concomitant background therapy required or allowed 
by the protocol when used within approved indication /dosage.
Medication numberA unique identifier on the label of each study  drug package in studies 
that dispense study  drug using an IRT s ystem.
Medication pack 
numberA unique identifier on the label of each drug package in studies that 
dispense study  treatment using an IRT s ystem
Non-investigational 
medicinal Product 
(NIMP)Products which are not the object of investigation (e.g. any  background 
therap y administered to each of the clinical trial subjects, regardless of 
randomization group, rescue medication, active drug run -ins etc.)
PartA single component of a study  which contains different objectives or 
populations within that single study . Common parts within a study  are: 
a single dose part and a multiple dose part, or a part in patients with 
established disease and in those with newly -diagnosed disease.
Patient An individual with the condition of interest
PeriodA minor subdivision of the study  timeline; divides phases into smaller 
functional segments such as screening, baseline, titration, washout, etc.

Novartis Confidential Page 12
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
Premature subject 
withdrawalPoint/time when the subject exits from the study  prior to the planned 
completion of all study  drug administration and assessments; at this 
time all study  drug administration is discontinued and no further 
assessm ents are planned.
Randomization 
numberA unique identifier assigned to each randomized subject, 
corresponding to a specific treatment arm assignment
Screen Failure A subject who is screened but is not treated or randomized
StageA major subdivision of the study  timeline; begins and ends with major 
study  milestones such as enrollment, randomization, completion of 
treatment, etc.
Study  completionPoint/time at which the subject came in for a final evaluation visit or 
when study  drug was discontinued whic hever is later.
Study  drug 
discontinuationPoint/time when subject permanentl y stops taking study  drug for any 
reason; may or may not also be the point/time of premature subject 
withdrawal.
Study  
drug/treatmentAny drug (or combination of drugs) administ ered to the subject as part 
of the required study  procedures; includes investigational drug, active 
drug run -ins or background therapy .
Study  treatmentAny drug administered to the study  participants as part of the required 
study  procedures; includes investigational drug (s), control(s) or non-
investigational medicinal product(s)
Study  treatment 
discontinuationWhen the subject permanently  stops taking study treatment prior to the 
defined stud y treatment completion date
Subject A trial participant (can b e a healthy  volunteer or a patient)
Subject numberA unique number assigned to each subject upon signing the informed 
consent. This number is the definitive, unique identifier for the subject 
and should be used to identify  the subject throughout the study for all 
data collected, sample labels, etc.
Treatment numberA unique identifier assigned in non-randomized studies to each dosed 
subject, corresponding to a specific treatment arm 
VariableA measured value or assessed response that is determined in specific 
assessments and used in data analysis to evaluate the drug being tested 
in the study
Withdrawal of 
consent (WoC)Withdrawal of consent from the study  is defined as when a subject 
does not want to participate in the study  any longer, anddoes not want 
any further visits or assessments, anddoes not want any further study 
related contact, and does not allow analy sis of alread y obtained 
biologic material

Novartis Confidential Page 13
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
Amendment 1 (August 2017)
Amendment R ationale : 
This Amendment is to provide minor adjustments and clarifications to the protocol.
Changes to the protocol : 
Section 3.6.1: I n the protocol, it is defined “Approximately  400 mL of blood is planned to 
be collected over a period of 8 weeks including the Scre ening visit, from each subject as 
part of the stud y.”   However, inconsistencies were discovered showing that the total 
blood volume adds up ~560 mL  based on the blood log (defined in the Site Operations 
Manual) . This was due to the collection of banking s amples for future use, if warranted b y 
study  results. The collection of banking samples are now removed (
108mL) , consequently, 
the total blood volume adds up to ~450 mL as originally  defined in the protocol. 
Section 3.1, Section 6.1.1, and Section 8 (Table 8 - 1, footnote 13) :The1 gram tablet 
formulation of calcium carbonate was changed to liquid formulation (4 mL) due to 
difficulty  in sourcing the tablet form ulation.
 
Section 5.2:  To ensure consistenc y, changes w eremade in the Prohibited Treatment : “a 
stable regimen for approximately  6 weeks prior to randomization ” to “a stable regimen for 
approximately  12 weeks prior to randomization” .
Section 8: T o be consistent with the protocol language , the time point s(2 and 4 hours) 
where VAS will be conducted is clarified in the Assessment schedule .
 
 
 
Minor corrections and updates were made as needed throughout the document.
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee ( IECs) and Health Authorities .
The changes described in this amended protocol may require IRB/ IEC approval prior to 
implementation.

Novartis Confidential Page 14
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
Protocol sy nopsis
Protocol number LIK066B2203
Title A randomized, open label, two-part, three -period, cross -over study to 
investigate the effects of carbohydrate in diet and to evaluate supplements on 
the gastrointestinal tolerability of LIK066 in overweight or obese subjects
Brief title Effects of carbohydr ate in diet and supplements on the GI tolerability of LIK066
Sponsor and 
Clinical Trial PhaseNovartis
Phase II
Intervention type Investigational drug
Study type Interventional 
Purpose and 
rationaleThe purpose of this study  is to 1) to assess whether or not a meal containing 
low carbohydrate in the form of glucose and galactose is associated with less 
diarrhea compared to a high carbohydrate meal; 2) to assess the potential 
effects of supplem ents such as psyllium or calcium carbonate on alleviating 
diarrhea. 
Primary 
Objective(s)To assess the effects of meals with different carbohydrate content on 
diarrhea 
To assess the effects of supplements (psyllium and calcium carbonate) on 
diarrhea 
Secondary
ObjectivesTo assess the effects of LIK066 and carbohydrate in meal on fecal parameters
Study design This randomized, open -label, two-part, three -period cross -over design will 
enroll approximately 24 overweight or obese subjects in each part (A and B) 
for a total of approximately 48 subjects over the course of the 25 day study. 
Part A will assess the effects of % carbohydrate (50%, 25% and 0%) in the 
breakfast meals on diarrhea when LIK066 is administered immediately before 
the breakfast.  Part B of the study will assess the effects of a concomitant 
treatment with a supplement (calcium carbonate or psyllium) on diarrhea when 
LIK066 is administered immediately before a breakfast meal with 50% 
carbohydrate. 
The study will consist of an up to 24 day screenin g period, a 3 day 
baseline/run in period, three periods of treatment of 3 days each with a 5 day 
washout  period in between each treatment period. Study completion will occur 
3 days after the last dose of LIK066.  The baseline, treatment, and washout 
perio ds will be conducted with subjects being domiciled (25 days 
consecutively). 
Diarrhea will be captured based on both reduced consistency (stools with 
Bristol Stool Chart (BSC) score of 6 or 7) and increased frequenc y (total 
number of bowel movements, total number of stools with BSC of 6 or 7).  
Symptoms such as urgency, bloating, flatus and abdominal pain will also be 
recorded for each bowel movement. The stool assessments include recording 
of the timing, weight, pH, consistency of stool using BSC according to the 
Assessment schedule . 
Population Overweight and obese subjects will be enrolled in this study.

Novartis Confidential Page 15
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
Key Inclusion 
criteriaMale and female aged 18 -65
Body mass index (BMI) of 25 -50 kg/m 2
HbA1c < 10% 
oral body temperature between 35.0- 37.5 °C
sitting systolic blood pressure, 90 -139 mm Hg
sitting diastolic blood pressure, 50 -89 mm Hg
sitting pulse rate, 40 -90 bpm
Key Exclusion 
criteriaPre-existing, clinically significant gastrointestinal, liver, cardiovascular, 
renal (including familial glucosuria) or other chronic medical condition 
which is considered serious or unstable, other than stable cardiovascular 
disease, stable adequately treated hypertension, dyslipidemia or other 
stable chronic disorders
Clinically significant GI disorder related to malabsorption or that may affect 
drug or glucose absorption
History of significant gastrointestinal surgery that could affect intestinal 
glucose absorption (e.g. bariatric surgeries including, Roux en Y gast ric 
bypass, sleeve gastrectomy, Nissen fundoplication)
Pregnant or lactating women
Type I diabetes
Study treatmentThe investigational drug, LIK066 tablets will be prepared by Novartis. 
Efficacy/PD 
assessmentsDiarrhea is the primary  endpoint in this study .
Key safety 
assessmentsPhysical examination
Body tem perature
Hematology
Blood chemistry
Urinalysis
Blood pressure
Pulse rate
ECG evaluation
Adverse events and serious adverse events
Other assessmentsStool pH, stool weight, and BSC score 
  
  




Novartis Confidential Page 16
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
Data analysis The primary analy sis will be performed by study part. The endpoint will be 
analyzed using a negative binomial mixed effects model with fixed effects of 
period, treatment, day, the period -by-day interaction, and the treatment -by-day 
interaction, and a random subject effect. An unstructured covariance matrix will 
be specified for the repeated observations on a subject within the same period. 
The least- squares mean and associated 80% CI for the number of diarrhea 
episodes per day for each treatment, and the estimated mean difference 
between each treatment, the p-value, and corresponding two-sided 80% CI, 
will be extracted from the model for each day, and summarized by a table and 
a line chart. Conclusions from the analysis will be based on treatment 
differences from all 3 days, collectively.
Key words SGLT1/2, GI tolerability, carbohydrate

Novartis Confidential Page 17
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
1 Introduction
1.1 Background
Obesity  has become a major global health problem that contributes causall y to and 
exacerbates many serious co-morbidities including hypertension, dyslipidemia, and 
importantly  type 2 diabetes (T2DM). In contrast to the numerous medicines that are available 
to treat these obesity -related diseases, relativel y few agents are available for the treatment of 
obesity  itself that are effective, safe or scalable to the size of the affected population 
(Morgen andSorensen 2014 ). A novel mechanism to lower body  weight is via inhibition of 
the sodium glucose co-transporters 1 and 2 (SGLTs) resulting in inhibition of the glucose 
absorption in the gut and reabsorption in the kidney  (Chao and Henry  2010). Inhealthy 
subjects, virtually  all of the filtered glucose is reabsorbed into the circulation and no glucose 
is detected in the urine. SGL T2 located in the segments 1 and 2 of the proximal tubule 
contributes to ~90% of reabsorption of the filtered glucose (Abdul -Ghani et al 2015). SGLT1 
is located in the more distal part of the proximal tubule, segment 3, and contributes to the 
remaining ~10% of filtered glucose. However, when SGLT2 is inhibited 
with empagliflozin 
(a SGL T2 inhibitor), SGTL 1 compensates for the reabsorption of filtered glucose and SGL T1 
is capable of reabsorbing >40% of filtered glucose load in a mouse model 
(Abdul -Ghani et al 2015; Macha et al 2014). In addition to expression in the kidney , SGLT1 
is also expressed in the small intestine, where it is require d for glucose and galactose 
absorption. Inhibition of enteric SGLT1 results in glucose and galactose malabsorption 
(Turk et
al1991), which results in calorie wasting and other potential endocrine -based weight 
loss mechanisms.
LIK066 is a potent dual inhibitor of SGLT1/2, which has been studied in healthy  subjects, 
patients with T2DM, and obese patients with elevated BMI.  LIK066 is generall y safe and 
well tolerated in the clinical studies being completed to date. LIK066 has a favorable 
pharmacokinetic profile (T1/2 10-16 hours), which allows once daily dosing.  LIK066 at 
150mg daily dose (as qd, bid or tid) results in a significant weig ht loss in obese patients and 
~6% of bod y weight loss was demonstrated after 12 week treatment.
The most frequent adverse event observed in a 12 
week study  in obese patients 
(LIK066X2201) associated with LIK066 was diarrhea. The observed diarrhea adverse event is 
likely  to be related to the complete inhibition of SGL T1 in the gut(Pfister et al 2011).  It is 
known that diarrhea observed in patients with SGL T1 inactivating mutation can be managed 
with elimination of glucose and galactose from the diet. Therefore, the observed 
LIK0 66-induced diarr hea may be managed by recommending a low carbohy drate (especiall y 
glucose and galactose) diet when LIK066 is administered. This study  is designed to assess the 
effects of meals with different carboh ydrate content and supplements on the incidence of 
diarrhe a associated with LIK066 treatment, and to assess the potential effects of 
LIK06 6 on 
incretin hormones (GL P-1andPYY) in overweight or obese subjects.

Novartis Confidential Page 18
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
The most relevant data for the present study are summar ized in the sections below. 
Fordetailed information, please refer to the Investigator's Brochure. 

Novartis Confidential Page 19
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
1.3 Clinical data
Four clinical studies have been completed for LIK066: a safet y/tolerability /efficacy  study in 
healthy  subjects and patients with T2DM, a mechanistic study  in patients with T2DM, and a 
proof -of-concept study  in obese patients with normogl ycemia or dysglycemia in the US, and 
an ethnic sensitivity  study  in healthy  Japanese subjects. 
1.3.1 Human safety  and tolerabi lity data
LIK066 was administered to 72 health y subjects in the US, 36 health y subjects in Japan and 
41 patients with T2DM and 127 obese patients in the US. Overall, single doses of up to 
350mg and repeated doses of up to 300 mg for 14 days in health y subjects were generall y 
safe and tolerated. Treatment with LIK066 at 150 mg qd for 12 weeks was also shown to be 
safe and tolerated. AEs were predominantl y diarrhea and related GI AEs after single doses or 
multiple doses in the higher daily  dose groups (≥150 mg as qd, bid or tid). No SAEs, 
withdrawals from treatment for AEs or significant clinical, laboratory , or ECG abnormalities 
were related to LIK066 administration.
With the exception of a small increase in urinary  specific gravity , BUN and expected 
glucosu ria, there were no consistent differences between LIK066 and placebo treated subjects 
in the prevalence of any specific laboratory  abnormality , the number of subjects observed to 
have an abnormalit y, or in the magnitude of specific laboratory  abnormalities. In the most 
recently  completed clinical trial (CLIK066X2201) in obese patients, 12 week treatment with 
LIK066 at 150 mg qd appeared to lead to a minor increase in subjects with urine ketones 
(urine dipstick) and anion gap, although there were no episodes of clinically  meaningful 
ketoacidosis.

Novartis Confidential Page 20
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
1.3.3 Human pharmacody namic data
Administration of LIK066 to healthy  subjects or obese patients lowered body  weight, 
consistent with a potentially  significant anti-obesity  effect, and in patients with T2DM, 
LIK066 lowered average and postprandial glucose levels, thus also demonstrating a 
significant antidiabetic effect. In obese patients with BMI ≥ 35 kg/m2, treatment with LIK066 
150 mg qd for 12 weeks led to significant efficacy on lowering body  weight 
(5.70% reduction). Two weeks of treatment with 75 mg bid or 50 mg tid led to similar effects 
on body  weight loss (2.39 % and 2.38%, respectively ). In healthy  volunteers, administration 
of LIK066 dose dependently  increased urinary  glucose excretion (UGE) to a maximal level of 

Novartis Confidential Page 21
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
approxima tely 80 g/24 hr in HVs after single and multiple oral daily (14 days) dosing. 
Inpatients with T2DM, administration of LIK066 (multiple daily  doses of 15 mg and single 
doses of 30, 300 mg) also increased urinary  glucose excretion, leading to a placebo -adjusted 
UGE 24of 90-100 g over 24-hours. A single dose administration of LIK066 at 15, 30 and 
300mg was associated with 30%, 31% and 48% reduction in the postprandial glucose levels 
during an oral glucose tolerance test (OGTT), respectivel y. In addition, two week average 
blood glucose levels measured using continuous glucose monitoring (CGM) decreased by 
41mg/dL following treatment with LIK066 15 mg once dail y for 2 weeks. 
1.4 Stud y purpose
The most frequent adverse event observed in a 12 week study  in obese patients 
(LIK066X2201) associated with LIK066 was diarrhea. This diarrhea is likely  to be related to 
complete SGL T1 inhibition.  It is known that diarrhea related to SGLT1 inactivating mutation 
can be managed with elimination of glucose and galactose from the diet (Martin et al 1996). 
Therefore, the observed LIK066 -induced diarrhea may be managed by recommending a low 
carboh ydrate diet when taking LIK066. The purpose of this study  is to assess the effects of 
meals with different carbohy drate content and supplements 
on the incidence of diarrhea 
associated with LIK066 treatment,  
 in overweight or obese subjects.
2 Study  objectives and endpoints
The objectives of this study  are: 1) to assess whether or not a meal containing low 
carboh ydrate in the form of glucose and galactose is associated with less diarrhea compared to 
a high carboh ydrate meal; 2) to assess the potential effects of supplements such as psy llium or 
calcium carbonate on alleviating diarrhea. 
2.1 Primary  objective(s)
Primary objective(s)Endpoints related to primary 
objective(s)
To assess the effects of meals with different 
carboh ydrate content on diarrhea Diarrhea (consistency  and 
incidence)
To assess the effects of supplements (psy llium and 
calcium carbonate) on diarrhea Diarrhea  (consistency  and 
incidence)
2.2 Secondary  objective(s)
Secondary objective(s) Endpoints related to secondary objective(s)
To assess the effects of LIK066 and 
carboh ydrate in meal on  fecal 
parametersStool samples (timing, assessment of 
consistency  with Bristol stool chart,  stool 
weight, stool pH)

Novartis Confidential Page 22
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
3 Investigational plan
3.1 Stud y design
This study  employ s a randomized, open -label, two-part, three -period, cross -over design. 
This is a non-confirmatory  study. Each part of the study will enroll approximately  
24overweight or obese subjects, thus, a total of approximately  48 subjects will be enrolled for 
the entire study . In each part of the study , each subject will be randomized to one of the 
3treatment sequences sh own in Figure 3 - 1 (Part A) and Figure 3 -2(Part B). 

Novartis Confidential Page 23
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
Part A of the study  will assess the effects of % carboh ydrate (50%, 25% and 0%) in the 
breakfast meals on diarrhea when LIK066 is administered immediately  before the breakfast.  
Part B of the study  will assess the effects of a concomitant treatment with a supplement 
(calcium carbonate or psy llium) on diarrhea when LIK066 is administered immediately  before 
a breakfast meal with 50% carboh ydrate. 
The primary  endpoint of this study  is the diarrhea events. Diarrhea is usually  defined by 
reduced consistency  and/or increased frequency of stools. Normal stool frequency  ranges 
from 3 per week to 2 per day. Bristol Stool Chart (BSC) is frequentl y used as a measure of 
consistency , and a score of 6 or 7 (pourable or watery  stool) isconsidered abnormal.  
Diarrhea even ts will be captured based on both reduced consistency  (stools with BSC score of 
6 or 7) and increased frequency  (total number of bowel movements, total number of stools 
with BSC of 6 or 7).  Symptoms such as urgency, bloating, flatus, and abdominal pain will 
also be recorded for each bowel movement.
The study  will consist of an up to 24 day  screening period, a 3 day  baseline/run in period, and 
three periods of treatment of 3 days each with a 5 day washout  period in between each 
treatment period. Study completion will occur 3 days after the last dose of LIK066.  
Thebaseline, treatment and washout periods will be conducted with subjects being domiciled 
for approximately  25 days (see Figure 3 -1and Figure 3-2). 
Screening (Day -28 to Day  -4)
Potential study  subjects will present to the clinical site for a screening visit where eligibility 
for the stud y will be evaluated.
Baseline/Run In (Day -3 to Day  -1)
Subjects who meet the inclusion/exclusion criteria at screening will be admitted to the clinical 
site on Day -3. A survey for food preference of each subject will be conducted so that meal 
menus can be provided to accommodate the usual diet habits of each individual. Asdiet 
changes may impact on the bowel movement habits, subjects participating in this study  will 
be encouraged to follow their usual dietary  habit whenever possible.  
During the baseline period, a standardized breakfast meal (600 calories with 
50% carboh ydrate, 15% protein and 35% fat) will be served; for lunch and dinner, menu 
options will be offered so that each subject can follow their usual diet following the standard 
nutritional guidance . 
Starting on Day -3 and continuing through the 25 days of domiciling period, stool assessments 
will take place whenever a subject has a bowel movement (Assessment schedule ). 
Starting from Day -2 at approximately  07.00, a 24-hour stool collection will be done for each 
subject. During Day 
-2 through Day 22, daily bowel movements will be monitored and 
collected, and stored in a refrigerated container and will be assessed by the study  staff 
according to the Bristol Stool Chart and bowel movement record. 

Novartis Confidential Page 24
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
The stool assessments include recording of the timing, weight, pH, consistency  of stool using 
Bristol Stool Chart,  
accordi ng to the 
Assessment schedule .
Day -1 Baseline A ssessment
Twent y-four (24) hour baseline stool samples will be collected from Day-1 to Day 1 mornin g 
(approximately  07.00 to 07.00) for various assessments of fecal parameters according to the 
Assessment s chedule .
 
 
 
On Day 
-1, at approximately  07.30, a 600 calorie standardized breakfast meal containing 50% 
carboh ydrate, 15% protein, and 35% fat will be served, and subjects will drink 250mL water 
imme diately  before breakfast during treatment periods . The time of drinking water will be 
defined as time zero for the measurement of baseline PD endpoints.  Each subject 
will 
consume the designated breakfast within 15 mins.  
 
 Lunch will be served at approximately  13.00 (after completion of the PD 
sample collection and at least 5 hours 
from breakfast), and dinner will be served at 
approximately  18.30. The timing of meals should be harmonized on all days (Day  -1, Day 3, 
Day 11, and Day  19) when PD are measured to minimize the effects of diurnal rhy thm.
 
All other samples and measurements will be taken according to the Assessment s chedule .
Part A :  Effects of Carbo hydrate in the Breakfast Meals
Trea tment Period I (Day 1 to Day 3); Period II (Day 9 to Day 11); Period III (Day 17 to 
Day 19)
Starting on the morning of Day 1 and through Day 3 of each treatment period, each subject 
will receive LIK066 50 mg qd in the morning immediately  before the assigne d breakfast meal 
according to their assigned treatment sequence. All subjects will take 50 mg LIK066 once daily  with 
their assigned breakfast meal containi ng either 50% carbohy drate, 25% carbohy drate, or no 
carbohy drate. For lunch and dinner, menu options will be offered so that the participants can follow 
their usual dietary  habits. These menus will be designed in accordance with the current
Recommended Dietary Guidelines (United States Department of Agriculture 2015). 
Theestimated calories consumed will be documented for each meal and for each subject. 
Aswith the baseline period, 24-hr stool collection will be done and stool assessment will be 
recorded for every  bowel movement of every  subject according to the Assessment s chedule .

Novartis Confidential Page 25
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
Twent y-four (24) hour stool samples will be collected from Day 3  to Day 4  m orning 
(approximately  07.00 to 07.00) of each treatment period for various assessments of fecal 
parameters accord ing to the Assessment s chedule .
 
arious assessments including 
UGE 24 and electrol ytes according to the Assessment s chedule .
 
 
At approximately  07.30, a 600 
calorie standardized breakfast meal conta ining 
either 50% or 25% or 0% carboh ydrate as designated will be served, and LIK066 50 mg will 
be administered immediately  before the breakfast meal. Each subject will consume the 
designated breakfast within 15 mins.  
 
 
Lunch will be served at approximately  13:00 (after completion of the PD sample collection 
and at least 5 hours from breakfast), and dinner will be served at approximately  18.30. 
Thetiming of meals should be harmonized 
on all days (Day  -1, Day 3, Day 11, and Day 19) 
when PD are measured to minimize the effects of diurnal rhy thm.
All other measurements and blood samples will be taken according to the 
Assessment schedule .
Washout Period I (Day 4 to Day 8); Period II (Day 12 to Day 16); Period III (Day 20 to 
Day 22) 
Study  subjects will also remain domiciled at the clinical site during the washout periods and 
no LIK066 will be admi nistered. There are no particular restrictions for the meals during the 
washout time period, and subjects can choose foods according to their eating habits and 
preference (meal menu to be provided offering varied choices). The estimated calories 
consumed w ill be documented for each meal for each subject.  As with the run -in and baseline 
period, all stool samples will be collected and bowel movement assessments will be recorded 
for every  subject. 
On Day 22, following the end of study  assessments, subjects will be discharged from the 
clinical site.
During the study , safet y assessments will include physical examinations, vital signs, standard 
clinical laboratory  evaluations (hematology , blood chemistry , and urinal ysis), adverse event 
and serious adverse event monitoring, as recorded in the Assessment schedule . 
 

Novartis Confidential Page 26
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
Figure 3-1 Part A : Effects of Carbohy drate in the Breakfast Meals
Screening 
Period 
Day-28 to 
-4Baseline 
Day -3 to 
-1Sequence Treatment 
Period 1 
Day 1-3Washout 
5 DaysTreatment 
Period II 
Day 9-11Washout 
5 DaysTreatment 
Period III 
Day 17-19Washout 
EOS Day  
20-22
Run-In 1 (n=8) 50% CHO 25% CHO 0% CHO
Run-In 2 (n=8) 25% CHO 0% CHO 50% CHO
Run-In 3 (n=8) 0% CHO 50% CHO 25% CHO
CHO = % carbohydrate content in the standardized breakfast meal
LIK066 50mg QD will be given in the morning immediately before the breakfast meal
Part B: Effects of Supplements (P syllium and Calcium carbonate)
The same Assessment Schedule will apply to Part B of the study  as described for Part A.  
Each subject will consume one of the three supplement treatment option s  (6 g psyllium, 
1gcalcium carbonate (to be provided in a 4mL  liquid, sugar free formulation) , or no 
supplement) according to the randomization assignment immediatel y after administration of 
50 mg LIK066, and before having the standardized breakfast meal, containing 50% 
carboh ydrate ( Figure 3 -2).  All supplement products will be the sugar free version.
Treatment Period I (Day 1 to Day 3); Period II (Day 9 to Day 11); Period III (Day 17 to 
Day 19)
Starting on the morning of Day 1 and through Day 3 of each treatment period, each subject 
will receive LIK066 50 mg qd in the morning , and then consume the designated supplements 
(6 g psyllium or 1g calcium carbonate or no supplement) according to their randomization 
assignment sequence. Immediately  after administration of LIK066 50 mg and the supplement, 
a 600 calorie breakfast meal containing 50% carboh ydrate will be served. For lunch and 
dinner, menu options will be offered for the participants to choose following their usual 
dietary  habits. These menus will be designed in accordance with the current Recommended 
Dietary  Guidelines. The estimated calories consumed will be documented for each meal and 
for each subject. As with the baseline period, all stools will be collected and assessment will 
be recorded for every  bowel movement of every  subject according to the Assessment schedule .
Twent y-four (24) hour stool samples will be collected from Day 3  to Day 4  m orning 
(approximately  07.00 to 07.00) of each treatment period forvarious assessments of fecal 
parameters according to the Assessment s chedule .
 
 
 

Novartis Confidential Page 27
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
On Day 3 of each treatment period, at approximately  07.30 in the morning, each subject will 
take LIK066 50 mg and then consume the supplement (6 g psyllium or 1g calcium carbonate 
or no supplement) as designated immediatel y before the breakfast. A 600 calorie breakfast 
meal containing 50% carbohy drate will be served and each subject will consume the breakfast 
within 15 mins.  
 Lunch will be 
served at approximately 13.00 (after completion of the PD sample collection and at least 
5hours from breakfast), and dinner will be served at approximately  18.30. The timing of 
meals should be harmonized on all days (Day 
-1, Day 3, Day 11, and Day 19) when PD are 
measured to minimize the diurnal rh ythm.
 
All other samples and measurements will be taken according to the Assessment s chedule .
Washout Period I (Day 4 to Day 8); Period II (Day 14 to Day 16); Period III (Day 20 to 
Day 22) 
Study  subjects will remain at the clinical site from the Day  4 through Day 8 of each treatment 
period for a washout period. During this time, no LIK066 will be administered. As with the 
run-in and baseline period, stool samples will be collected and bowel movement assessments 
will be recorded for every  subject. 
On Day 22, following the end of study  assessments, subjects will be discharged from the 
clinical site.
During the study , safet y assessments will include physical examinations, vital signs, standard 
clinical laboratory  evaluations (hematology , blood chemistry , and urinal ysis), adverse event 
and serious adverse event monitoring, as recorded in the Assessment schedule . 
 
Figure 3-2 Part B: Effects of Supplements in the Breakfast Meals*
Screen ing 
Period 
Day-28 to 
-4Baseline 
Day -3 to 
-1Sequence Treatment 
Period 1 
Day 1-3Washout 
5 DaysTreatment 
Period II 
Day 9-11Washout 
5 DaysTreatment 
Period III 
Day 17-19Washout 
EOS Day  
20-22
Run-In I (n=8) NS Psyllium CC
Run-In II (n=8) Psyllium CC NS
Run-In III (n=8) CC NS Psyllium
*CHO = % carbohydrate content in the standardized breakfast meal (50%) for all groups 
LIK066 (50 mg QD) and supplement will be administered immediately before the breakfast meal
NS = No supplement
CC = Calcium Carbonate (1 gram)
Psyllium = 6 grams

Novartis Confidential Page 28
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
3.2 Rationale of study  design
This is a mechanistic study  to investigate the effect of percentage carboh ydrate in the 
breakfast meal on the LIK066 -induced diarrhea and potential treatments with a supplement in 
overweight or obese subjects. The study  will use a randomiz ed, open -label, two-part, 
three -period, cross- over design in each part of the study .
An open label design is considered appropriate because all the primary  and secondary  
endpoints assessed in this stud y are objective measures in nature. A crossover design is 
ideal as comparisons among treatment groups are based on within- subject differences 
which are associated with less variability  than between- subject differences. The main 
objective is to assess wheth er or not the diarrhea adverse event can be alleviated by  
reducing or removing carbohy drate containing glucose and galactose in the meal or by  
concomitant administration of supplements, therefore, placebo control is not needed.
The design of two parts (Par t A and Part B) with 3 treatment periods, cross- over design is 
preferred because a single part, six treatment periods cross- over design requires longer 
duration of domiciling which may  lead to operational complexity
 such as difficulty  in 
recruitment and hi gher drop-out rates. The two parts, three periods design is also preferred 
from statistical perspective because it yields the most statistically  efficient design for 
addressing the clinical questions.
A five day  washout period is considered sufficient base d on the fact that limited diarrhea 
episodes were observed on the following day after the last dose of 50 mg q d (one out of
40patients showed diarrhea on day  15 after 14 day  dosing in LIK066X2201).
A standardized breakfast meal (together with menu options for lunch and dinner) enables 
each subject to choose the diets following their usual eating habits during the run -in will 
normalize the bowel movement habit of each subject under similar meal conditions for the 
purpose of comparison during the treatment periods.
The overweight or obese subjects in this study  will closely  represent the patient population 
for LIK066, which is being developed as a pharmacotherap y for obesity.
Therefore, the study  design is considered adequate and appropriate to address the primary 
objectives, the stool consistency  and incidence of diarrhea associated with LIK066 treatment, 
which are endpoints that can be measured objectively .

Novartis Confidential Page 29
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
3.4 Rationale for choice of comparator
Not applicable.

Novartis Confidential Page 30
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
3.5 Purpose and timing of interim analy ses/design adaptations
An interim analy sis is not planned, but may be conducted before all subjects complete the 
study  if deemed necessary . Depending on the progress of the trial, the analysis may be 
conducted to support decision making concerning the current clinical study , thesponsor’s 
clinical development strategy  in general, or in case of any  safet y concerns. 
3.6 Risks and benefits
There is no anticipated therapeutic benefit expected for subjects participating in this study . 
The risk to participants in this trial will be minimi zed by adherence to the inclusion/exclusion 
criteria, close clinical monitoring during the treatment periods, and stopping rules outlined in 
Section 7.5.
Risks of LIK066 administration in human subjects may include the development of 
gastrointestinal adverse reactions, postural hy potension due to volume depletion, ketoacidosis, 
urinary  tract infection, genitourinary  infection, renal and hepatic toxicity , and changes in 
calcium homeostasis with subsequent eff ects on bones, hy
pergl ycemia and hy poglycemia.
Doses of LIK066 proposed in this study  have been tested and deemed safe in healthy  subjects, 
patients with T2DM and obese patients. Subjects should be closely  monitored and treated 
according to the standard of care if deemed necessary  by the principle investigator.  LIK066 is 
considered an aneugen at extremely  high doses. With the doses and treatment duration 
proposed in this study , more than 10-fold exposure multiple is maintained relative to the 
threshold NOE L exposure for aneugenicit y. LIK066 is not anticipated to increase the risk of 
adverse developmental or reproductive outcomes in humans when administered at the highest 
planned clinical dose of 150 mg. Women of child bearing potential should be informed that 
taking the study  drug may involve unknown risks to the fetus if pregnancy  were to occur 
during the study  and agree that in order to participate in the study  they must adhere to the 
contraception requirement for the duration of the study  (Section 4.2). If there is any question 
that the subject will not reliably  comply , they  should not be entered in the study .
The supplements used in this study  are generall y well tolerated and widely  used as the OTC 
supplemen ts. Potential risks associated with psyllium are bloating and flatulence, and those 
associated with calcium carbonate are constipation, gas and burping. 
Blood samples will be collected frequentl y during the study  either via venipuncture or cannula. 
Additi onal samples for monitoring of any safet y findings would be in addition to 
this. This is 
not considered to be a risk for this population. Risks associated with blood collection include 
pain, swelling and/or bruising at the inserti on site of the needle. Alt hough rare, localized clot 
formation, infections and nerve damage may  occur. Lightheadedness and/or fainting may  also 
occur during or shortly  after the blood draw.
There may  be unknown risks to LIK066 which may be serious and unforeseen.

Novartis Confidential Page 31
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
3.6.1 Blood sample volum es
Approximately  450mL of blood is planned to be collected over a period of 8 weeks including 
the Screening visit, from each subject as part of the study . Additional samples for monitoring 
of any safety  findings would be in addition to this. This is not considered to be a risk for this 
population.
Timings of blood sample collection are outlined in the Assessment Schedule, Section 8.1.
A summary  blood log is provided in the Site Operations Manual, together with instructions 
for all sample collection, processing, storage
,and shipment information.
See Section 8.9 regarding the potential use of residual samples. 
4 Population
The study  population will consist of male and female overweight or obese subjects. 
A total of approximately 48 patients will be enrolled in the study and randomized. At least 
36subjects are expected to complete the study . 
The investigator must ensure that all subjects meet the subsequent eligibility  criteria at 
screening . No additional criteria should be applied by the investigator to ensure that the study 
population is representative of all eligible subjects. A relevant record (e.g. checklist) of the 
eligibility  criteria must be stored with the documentation at the study  site. 
Deviation from an y entry criterion excludes a patient from enrollment into the study .
4.1 Inclusion criteria
Overweight or Obese Subjects eligible for inclusion in this study  must fulfill allof the 
following criteria:
1.Written informed consent must be obtained before any  assessment is performed.
2.Male and female subjects age 18 to 65 years, with stable health condition as determined 
by past medical history , phy sical examination, electrocardiogram, and laboratory  tests at 
screening.
3.Subjects with a body  mass index (BMI) of 25 - 50 kg/m2at screening 
4.HbA 1c< 10% at screening. If treated with antidiabetic medications (other than prohibited 
medications), subjects must be on a stable dose fo r 12 weeks prior to randomization and 
maintain the dose until the end of the stud y.
5.Able to communicate well with the I nvestigator, to understand and comply with the 
requirements of the study.

Novartis Confidential Page 32
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
6.At screening and baseline,  vital signs (s ystolic and diastolic blood pressure and pulse rate) 
will be assessed in the sitting position after the subject has rested for at least three (3) 
minutes, and again when required after three (3) minutes in the standing position 
Investigators can be guided by  the following rang es:
oral body temperature between 35.0 -37.5 °C
sitting sy stolic blood pressure, 90 -139 mm Hg
sitting diastolic blood pressure, 50- 89 mm Hg
sitting pulse rate, 40 -90 bpm
If vital signs are out
-of-range, the Investigator may  obtain two additional readings ,so that 
up to three (3) consecutive assessments are made, each after at least 30 minutes (one hour 
is recommended), and with the subject seated quietly  during the five (5) minutes 
preceding the assessment. At least the last reading must be within the rang es provided 
above in order for the subject to qualify.
When blood pressure and pulse will be taken again after 3 minutes standing, there shall be 
no more than a 20 mm Hg drop in s ystolic or 10 mm Hg drop in diastolic blood pressure 
and increase in heart ra te (>20 bpm) associated with clinical manifestation of postural 
hypotension.
All blood pressure measurements at other time -points should be assessed with the subject 
seated, unless stated otherwise in the protocol design, and utilizing the same arm for eac h 
determination.
4.2 Exclusion criteria
Overweight or Obese Subjects fulfilling any of the following criteria are noteligible for 
inclusion in this study :
1.Pre-existing, clinicall y significant gastrointestinal, liver, cardiovascular, renal (including 
familial glucosuria) or other chronic medical condition which is considered serious or 
unstable, other than stable cardiovascular disease, stable adequatel y treated hypertension, 
dyslipidemia or other stable chronic disorders
2.Clinically  significant GI disorder rela ted to malabsorption or that may  affect drug or 
glucose absorption (e.g. swallowing disorder, severe GI motility  disorder, chronic diarrhea, 
glucose/galactose/lactose intolerance)
3.History  of significant gastrointestinal surgery  that could affect intestinal glucose 
absorption (e.g. bariatric surgeries including, Roux en Y gastric b ypass, sleeve 
gastrectom y, Nissen fundoplication)
4.History  of hypersensitivity  to the study  drugs, or to drugs of similar chemical classes.
5. Pregnant or nursing (lactating) women, wh ere pregnancy  is defined as the state of a female 
after conception and until the termination of gestation, confirmed by  a positive hCG 
laboratory  test
6.Women of child- bearing potential, defined as all women phy siologically  capable of 
becoming pregnant, unle ss they  are using basic methods of contraception during dosing of 
study  treatment.

Novartis Confidential Page 33
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
Basic contraception methods include:
Total abstinence (when this is in line with the preferred and usual lifest yle of the 
subject. Periodic abstinence (e.g., calendar, ovula tion, sy mptothermal, post -ovulation 
methods) and withdrawal are not acceptable methods of contraception.
Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y) or tubal ligation (h ysterectomy  is acceptable) at least si x weeks before 
taking stud y treatment. In case of oophorectomy alone, only when the reproductive 
status of the woman has been confirmed b y follow up hormone level assessment.
Male sterilization (at least 6 months prior to screening). For female subjects on the 
study , the vasectomized male partner should be the sole partner for that subject.
Barrier methods of contraception: Condom or Occlusive cap (diaphragm or 
cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal suppository .
Use of oral, injected or implanted hormonal methods of contraception or other forms 
of hormonal contraception that have comparable efficacy  (failure rate <1%), for 
example hormone vaginal ring or transdermal hormone contraception.
Placement of an intrauterine device (I UD) or intrauterine s ystem (IUS).
In case of use of oral contraception women should have been stable on the same pill 
for a minimum of 3 months before taking stud y treatment.
Women are considered post -menopausal and not of child bearing potential if they  have 
had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile 
(e.g. age appropriate, history  of vasomotor s ymptoms) or have had surgical bilateral 
oophorectom y (with or without hy sterectomy ) or tubal ligation (hy sterectomy  is 
acceptable) at least six weeks ago. In the case of oophorectom y alone, onl y when the 
reproductive status of the woman has been confirmed by  follow up hormone level 
assessment is she considered not of child bearing potential
7.Patients with ty pe 1 diabetes, or history  of acute diabetic complications such as 
ketoacidosis or h yperosmolar state (coma) within the 6 months prior to screening
8.Evidence of significant diabetic complications such as sy mptomatic neuropathy , severe 
diabetic retinopath y, diabetic nephropat hy, diabetic gastroparesis or enteropathy
9.Use of prohibited medications, refer to Section 5.2 .
10.Evidence of clinically significant renal or liver disease/injury including:
eGFR less than 60 mL/min/1.73m2at screening.
Patients with macroalbuminuria as determined b y spot urine albumin:creatinine 
ratio >300 mg/g at screening.
Abnormal liver function tests at screening:
ALT, AST, GGT, alkaline phosphatase > 2 x UL N.
serum bilirubin > 1.5 x ULN
11.Evidence of urinar y obstruction or difficult y in voiding at screening 
12.Symptomatic genital or urinary  tract infection in the 4 weeks prior to first study  visit
13.Any uncontrolled endocrinopathy  including thy roid disease. Patients with an underl ying 
endocrinopathy should be on stable treatment for 3 months prior to screening
14.Evidence or medical history  of clinicall y significant ECG abnormalities 

Novartis Confidential Page 34
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
15.Any of the following within 6 months of screening:
Acute coronary  syndrome (ACS)
coronary  artery  bypass surgery , balloon angioplasty , coronary  stent(s) in situ
peripheral arterial disease
congestive heart failure NYHA class I-IV
16.History  of autonomic dy sfunction (e.g. history  of fainting, clinicall y significant orthostatic 
hypotension, clinically  significant sinus arrhy thmia).
17.Significant blood loss equaling at least one unit of blood (500 ml) or a blood transfusion 
within 3 months prior to screening
18.Evidence of immunodeficiency  diseases, including a positive HIV (ELISA and Western 
blot) test at screening
19.History  of drug or alcohol abuse within the 12 months prior to initial dosing or evidence 
of such abuse as indicated by  the laboratory  assays conducted during the screening or tests 
conducted during baseline evaluations
20.Malignancy  inclu ding leukemia and l ymphoma (not including basal cell skin cancer) 
within 5 y ears prior to screening
21.Any finding during screening assessments (phy sical examination, vital signs, or clinical 
lab assessments), surgical or medical condition which might signifi cantl y alter the 
absorption, distribution, metabolism, or excretion of drugs, or which may  jeopardize the 
subject, in the investigator’s judgment, in case of participation in the study .
22.Subjects who experienced ketoacidosis, lactic acidosis , or hy perosmola r coma within 
6months of Screening Visit, or between Screeni ng Visit and Baseline Day -1. 
Noadditional exclusions may  be applied by  the investigator, in order to ensure that the 
study  population will be represe ntative of all eligible subjects.
5 Restrictio ns for Study  Subjects
During recruitment, screening/informed consent review, and baseline visit, the subjects must 
be informed and reminded of the restrictions outlined in this section.
5.1 Contraception requirements
Please refer to exclusion criteria ( Section 4.2 ) for details of contraception requirements for the study .
5.2 Prohibited treatment
Except for medication which may  be required to treat adverse events, no medication including 
OTCs other than study drugs will be allowed from the first dosing until all of the 
Study Completion evaluations have been conducted. If needed, acetaminophen or ibuprofen is 
acceptable for incidental and limited use. Aspirin, antihy pertensive, dyslipidemia, COPD and 
GERD medication s including PPIs are allowed but subjects must be on a stable regimen for 
12 weeks or more prior to randomization ( Section 6.10) .

Novartis Confidential Page 35
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
The following medications are prohibited during the study :
Antidiabetic dru gs including injectable antidiabetic medic ations (such as insulin and 
GLP-1 agonists), SGL T and alpha -glucosidase inhibitors are NOT allowed during the 
study . Patients must be on a stable regimen for approximately  12 weeks prior to 
randomization if treated with other oral antidiabetic medications.
Treatment with drugs that affect gastric motility  (e.g. ery throm ycin)
Treatment with drugs that have a high incidence of diarrhea
Drugs which act primarily  in the GI tract (e.g. Orlistat, acarbose)
Chronic systemic steroid treatment or s ystemic steroids for > 7 consecutive day s for 
worsening of an underl ying condition within 4 weeks of screening. Use of topical or 
inhaled steroids is permitted
Use of other investigational drugs at the time of enrollme nt, or 
within 30 day s or 
5half-lives of enrollment, or longer if required b y local regulations, and for any  other 
limitation of participation in an investigational trial based on local regulations
Unless allowed b y the study  protocol, use of an y other prescripti on drugs, new herbal 
supplements, within four (4) weeks prior to initial dosing, and/or over -the-counter (OTC) 
medication, new dietary supplements (vitamins included), within 3 day s prior to initial 
dosing. 
Subjects may need to discontinue the study  treatment if treated with any of the prohibited 
medications during the study . Concomitant and prior medications (dose, regimen, indication 
and treatment duration) must be recorded in the CRF.
5.3 Dietary  restrictions and smoking
 
 
No alcohol for approximately  24 hours before the study  visits until the Study  Completion 
evaluation.
No cigarettes/use of nicotine products are allowed on the study .
No grapefruit or grapefruit juice is to be consumed for approximately  7 days prior to 
dosing until 7 day s following the last dose. 
 
 

Novartis Confidential Page 36
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
While domiciled, subjects will be provided a standardized breakfast meal according to their 
randomization assignment below for Part A and B:
Part A : Effects of carbohydrate in the breakfast meal
The breakfast meal will contain 600 calories providing 50% carboh ydrate, 15% protein 
and 35% fat. This meal willbe served at approximately  07.30, immediately  after LIK066 
adminis
tration. The breakfast meal should be consumed within 15 mins.
The breakfast meals during each treatment period will include the following and according 
to the randomization assignment:
600 calories - 50% carbohy drate, 15% protein, and 35% fat
600 calories - 25% carbohy drate, 40% protein, and 35% fat
600 calories - 0% carbohy drate, 65% protein, and 35% fat
Part B: Effects of supplements
All breakfast meals in Part B treatment periods will include approximately  600 calories 
containing 50% carboh ydrate, 15% protein, and 35% fat, and ser ved at approximately  
07.30 immediately  after administration of LIK066, then the designated supplements 
(psyllium, calcium carbonate or no supplement) according to randomization.
In both study  parts and during each treatment period, lunch will be se
rved at approximately 
13.00 (after completion of the PD sample collection and at least 5 hours from breakfast), and 
dinner will be served at approximately  18.30. The timing of meals should be harmonized on 
all days (Day  
-1, Day 3, Day 11, and Day 19) when PD are measured to minimize the effects 
of diurnal rh ythm.  A snack may  be served at approximately 20.00 if needed .
Lunch and dinner meals will be provided as a menu option, and study  participants can choose 
from the menu based on their usual eating habits.
Further details on the specified meals and potenti al meal menu options will be provided in the 
SOM.
A meal recor d will confirm timing and consumption of meal. A copy of the diet with content 
and nutritional information (e.g., amount of protein, sodium, carbohydrates, fat and calories 
for each meal) will be provided to the Sponsor upon request.
5.4 Other restrictions
No strenuous ph ysical exercise (e.g. weight training, aerobics, football) for 3 day s before 
dosing until after Stud y Completion evaluation.
During the domiciled period, study  participants are encouraged to maintain usual activity  
level in the study  site (e.g. , light to moderate walking) to minimize altered bowel habits 
associated with inactivit y. 

Novartis Confidential Page 37
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
6 Treatment
6.1 Stud y treatment
The investigational drug, LIK066, 50 mg tablets, will be prepared by  Novartis and supplied to 
the Investigator as open labeled bulk medicat ion. Supplements (Sugar Free version) including 
psyllium and calcium carbonate will be sourced by  the Site. 
Details on the requirements for storage and management of study  treatment, and instructions 
to be followed for subject numbering, prescribing/dispe nsing and taking study  treatment are 
outlined in the Site Operations Manual.
6.1.1 Investigational treatment and control drugs
Formulation Unit Dose Packaging Provided by
LIK066 Tablet 50 mg Open -label, bulk, blister -pack Novartis
Psyllium Powder 6 grams Over the counter Sourced by site
Calcium carbonate Liquid1 gram
(4mL 
equivalent 
sugar free 
formulation)Over the counter Sourced by site
6.1.2 Additional study  treatment
No additional treatment beyond the investigational drug LIK066 and the supplements 
(psyllium and calcium carbonate) are included in this trial.
6.2 Treatment arms
Study  treatments are defined as:
A:  Daily  dose of 50 mg LIK066+50% carbohy drate
B:  Dail y dose of 50 mg LIK066+25% carboh ydrate
C:  Daily  dose of 50 mg LIK066+0% carboh ydrate
D: D aily dose of 50 mg LIK066+50% carbohy drate+ 6 g ps yllium
E: Daily  dose of 50 mg LIK066+50% carbohy drate+1g calcium carbonate (1 g calcium 
carbonate in 4mL  liquid sugar -free formulation)
In each part of the study , subjects will be randomized to one of the following 3 treatment 
sequences in the ratio of 1:1:1.

Novartis Confidential Page 38
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
Table 6-1 Definition of treatment sequences
Part A
Sequence Period 1 Period 2 Period 3
1 A B C
2 B C A
3 C A B
Part B
Sequence Period 1 Period 2 Period 3
4 A D E
5 D E A
6 E A D
6.3 Treatment assignment and randomization
Randomized treatment will be assigned to individual subjects by way of a randomization 
number, which will be in the range of  and  in Part A and Part B, 
respectivel y.
The randomization number is only used to identify  which treatment the subjects have been 
randomized to receive.  The Subject number assigned to a subject at screening remains the 
unique identifier for the subject throughout the study .  For information on subject numbering, 
please see ‘Subject numbering’ section in the SOM.
Replacement randomization numbers will be in the range of  for Part A and 
 for Part B. If a subject requires a replacement, the replacement subject will be 
assigned a randomization number corresponding to the original subject (e.g. Subject  
would replace Subject ).  Any additional subjects enrolled will use sequential subject 
numbering.
The table below details the general details of the numbering of the subjects once randomized 
to treatment:
Table 6-2 Randomization assignment numbering
Cohort Randomization numbers Replacement randomization numbers
Part A (n=24)
Part B (n=24)
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased. Treatment allocation cards will be produced by  or under the 
responsibility  of Novartis Drug Suppl y Management using a validated system that automates 
the random assignment of treatment arms to randomization numbers in the specified ratio.
Therandomization scheme for subjects will be review ed and approved by a m ember of the 
Randomization Office.
There will be no stratification of randomization. Block randomization will be used to generate 
the treatment allocation cards.

Novartis Confidential Page 39
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
Follow the details outlined in the Site Operations Manual regarding theprocess and timing of 
treatment assignment and randomization of subjects.
6.4 Treating the subject
LIK066 50 mgwill be administered to the subject orally by the study  personnel at the 
investigator site.  See the Site Operations Manual for further details.
6.5 Permitted dose adjustments and interruptions of study  treatment
Study  treatment dose adjustments and/or interruptions are not permitted. 
For subjects who are unable to tolerate the protocol-specified dosing scheme, treatment 
should be discontinued. These changes must be recorded on the Dosage Administration 
Record CRF.
6.6 Emergency  breaking of assigned treatment code
This is an open label, non-placebo control study; therefore emergency  code breaks are not 
applicable. 
6.7 Treatment exposure and compliance
Study  medication will be given at the site by study personnel as subjects will be domiciled 
during the entire stud y treatment periods.
 
6.8 Recommended treatment of adverse events
Based on prior clinical experience with LIK066, which was administered to more than 
200subjects at doses up to 350 mg single dose or up to 150 mg for 12 weeks, LIK066 -related 
AEs can be managed by clinical monitoring including vital signs and blood tests. If diarrhea 
occurs, it can be treated with oral rehydration therapy  if needed . More aggressive treatment, 
ifrequired, will be performe d at the discretion and direction of the investigator, with timely 
communication with the sponsor. Stopping rules (Section 7.4) will be applied as appropriate. 
Medication used to treat AEs must be recorded on the 
Concomitant medications/Significant 
non-drug therapies CRF.
6.9 Rescue medication
This is not a therapeutic study ;therefore, rescue medication use is not applicable.

Novartis Confidential Page 40
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
6.10 Concomitant treatment
Except for medication which may  be required to treat adverse events , no medication including 
OTCs other than study drugs will be allowed from the first dosing until all of the 
Study Completion evaluations h ave been conducted. If needed, acetaminophen or ibuprofen is 
acceptable for incidental and limited use. Aspirin, antihypertensive, dyslipidemia, COPD and 
GERD medications are allowed but subjects must be on a stable regimen for 12 weeks or 
more prior to randomization.
The investigator must instruct the subject to notify  the study  site about any new medications 
he/she takes after the subject was enrolled into the study .
All prescription medications, over-the-counter drugs and significant non-drug therapies 
(including physical therapy  and blood transfusions) administered or taken within the 
timeframe defined in the entry  criteria prior to the start of the study  and during the study , must 
be recorded on the Concomitant medications/Significant non- drug therapies CRF.
Medication entries should be specific to trade name, the single dose and unit, the frequenc y 
and route of administration, the start and discontinuation date and the reason for therapy .
Each concomitant drug must be individually  assessed against all exclusion criteria/prohibited 
medication. If in doubt, the investigator should contact Novartis before randomizin g a subject 
or, if the subject is already  enrolled, to determine if the subject should continue participation 
in the study .
7 Study  completion and discontinuation
7.1 Stud y completion and post -stud y treatment
Each subject will be required to complete the study  in its entirety  and thereafter no further 
study  treatment will be made available to them.
Study  completion is defined as when the last subject completes their Study  Completion visit, 
and any repeat assessments associated with this visit have been documented and followed- up 
appropriatel y by the Investigator, or in the event of an early study  termination decision, the 
date of that decision.
All subjects should have a safety  follow -up call conducte d 30 days after last visit. 
Theinformation collected is kept assource documentation.  All SAEs reported during this 
time period must be reported as described in Section 9.2 and the Site Operations Manual.  
Ifunable to contact the subject, documentation of attempts should be recorded in the source 
documentation.
7.2 Discontinuation of study  treatment
Discontinuation of study  treatment for a subject occurs when study  treatment is stopped 
earlier than the protocol planned duration. Discontinuation of study  treatment can be decided 
by either the subject or the investigator.

Novartis Confidential Page 41
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
Study  treatment must be discontinued under the following circumstances:
Subject decision -subjects may  choose to discontinue study  treatment for any  reason at 
any time.
The investigator believes that co ntinuation would negativel y impact the safety of the 
subject or the risk/benefit ratio of trial participation.
Any protocol deviation that results in a significant risk to the subject’s safety .
Pregnancy
Use of prohibited treatments.
Study  treatment of individual subject will be discontinued when that subject experiences:
Clinically  significant diarrhea, suspected to be related to the study  drug, that may  put the 
subject at risk at the discretion of the investigator and in consultation with the sponsor
Clinically  significant s ymptomatic orthostasis confirmed b y repeated orthostatic blood 
pressure changes (more than a 20 mmHg drop in sy stolic or 10 mmHg drop in diastolic 
blood pressure and increase in heart rate >20 bpm (compared to the sitting results) when 
blood pressure and pulse are taken after at least 3 minutes standing)
Clinically  significant urinary  tract or genitourinary  infections, at the discretion of the 
investigator and in consultation with the sponsor if deemed necessary .
Clinically  symptomatic hypogly cemia confirmed by  repeated blood glucose levels 
(<56 mg/dL).
Ketoacidosis (s ymptoms of ketoacidosis include nausea, vomiting, abdominal pain, 
unusual tiredness and trouble breathing) confirmed by  blood pH and ketones bodies in 
both plasma and urine . 
Any laboratory  abnormalities that in the judgment of the investigator, taking into 
consideration the subject’s overall status, prevents the subject from continuing 
participation in the study .
Any hospitalization, or other SAE, that is suspected to be re lated to the study  treatment.
If discontinuation of study  treatment occurs, the investigator must determine the primary 
reason for the subject’s premature discontinuation of study  treatment and record this 
information on the Dosage Administration CRF.
Subjects who discontinue study  treatment or who decide they do not wish to participate in the 
study  further should NOT be considered withdrawn from the study  UNLESS they  withdraw 
their consent. Where possible, they should return for the assessments indicat ed in the 
Assessment table . If they fail to return for these assessments for unknown reasons, every 
effort (e.g. telephone, e -mail, letter) should be made to contact the subject/pre -designated 
contact. Th is contact should preferabl y be done according to the study visit schedule.

Novartis Confidential Page 42
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
7.3 Withdrawal of informed consent
Subjects may voluntaril y withdraw consent to participate in the study  for any reason at any 
time.
Withdrawal of consent from the study  is defined as when a subject:
Does not want to participate in the study  anymore and
Does not want an y further visits or assessments and
Does not want an y further study  related contacts and
Does not allow anal ysis of already  obtained biologic material.
In this situation, the investigator must make every  effort (e.g. telephone, e-mail, letter) to 
determine the primary  reason for the subject’s decision to withdraw his/her consent and 
record this information.
Study  treatment must be discontinued and no further assessments co nducted, and the data that 
would have been collected at subsequent visits will be considered missing.
Further attempts to contact the subject are not allowed unless safety  findings require 
communicating or follow -up.
7.4 Lost to follow -up
For subjects whose st atus is unclear because they  fail to appear for study  visits without stating 
an intention to discontinue or withdraw, the investigator should show "due diligence" by 
documenting in the source documents steps taken to contact the subject, e.g. dates of 
telephone calls, registered letters, etc. A subject cannot be formally  considered lost to 
follow -up until his/her scheduled end of stud y visit would have occurred.
7.5 Stud y Stopping rules
The principal investigator and the sponsor will continually  review adverse events and 
laboratory  findings throughout the study . The study  will be placed on hold and based on full 
review of the clinical data and discussion with the investigator may be halted if the principal 
investigator and the sponsor consider that the number an d/or severity  of adverse events justify 
discontinuation of the study ; including cumulative cases of clinicall y significant diarrhea, 
urinary  tract infections, severe adverse events, clinically  significant laboratory  changes 
suspected to be related to the study drug, or serious adverse event suspected to be related to 
the study  drug.
7.6 Early study  termination by  the sponsor
The study  can be terminated by  Novartis at any  time for any  reason. This may  include reasons 
related to the benefit/ risk assessment of pa rticipating in the study , practical reasons (including 
slow enrollment), or for regulatory  or medical reasons. Should this be necessary , subjects must 
be seen as soon as possible and treated as a pre maturely  withdrawn subject. The investigator may  be 
informed of additional procedures to be followed in order to ensure that adequate consideration is 
given to the protection of the subject’s interests. Theinvestigator will be responsible for informing 
IRBs/IECs of the early  termination of the trial .

Novartis Confidential Page 43
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
8 Procedures and assessments
8.1 Assessment schedule
Subjects should be seen for all visits/assessments as outlined in the assessment schedule or as close to the designated day /time as possible.
Missed or rescheduled visits should not lead to automatic discontinuation. Subjects who prematurely discontinue the study forany rea
son 
should be scheduled for a visit as soon as possible, at which time all of the assessments listed for the final visit will be performed. At this 
final visit, all dispensed investigational product should be reconciled, and the adverse event and concomita nt medications recorded on the CRF .
Table 8-1 Assessment Schedule
Epoch Screening Run In Treatment Period 1 Treatment Period 2
Visit Name Screening Baseline/Run -in Treatment Washout Treatment
Visit Numbers11 101 102 199 201 202 203 204 205 206 207 299 301 302 303
Study Day(s) -28 to -4 -3 -2 -1 1 2 3 4 5 6 7 8 9 10 11
Time (post -dose) - - - Predose: 0 H 0.5h 2h 4h - - Predose: 0 H 2h 4h - - - - - - - Predose: 0 H 2h 4h
Informed consent X
Inclusion / Exclusion 
criteriaS S2
Medical history/current 
medical conditionsX X
Demography X
Physical Examination S S S S
Hepatitis and HIV Screen S
Alcohol Test, Drug Screen, 
and Cotinine TestS S
Electrocardiogram (ECG) X X X X
Pregnancy test X3X4
Vital Signs5X X X X
Body W eight X X X X

Novartis Confidential Page 44
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
Epoch Screening Run In Treatment Period 1 Treatment Period 2
Visit Name Screening Baseline/Run -in Treatment Washout Treatment
Visit Numbers11 101 102 199 201 202 203 204 205 206 207 299 301 302 303
Study Day(s) -28 to -4 -3 -2 -1 1 2 3 4 5 6 7 8 9 10 11
Time (post -dose) - - - Predose: 0 H 0.5h 2h 4h - - Predose: 0 H 2h 4h - - - - - - - Predose: 0 H 2h 4h
Body Height X
Hematology X X X X
Clinical Chemistry X X X X
Urinalysis X X X X
24 hour stool collection9X X X
Bowel movements10X X X X X X X X X X X X X X
Meal11X12X X X X X X X X
Supplements13X X X X X X
Dose administration14X X X X X X X X X
Concomitant medications X X X
Serious Adverse Events As Required
Adverse Events As Required

Novartis Confidential Page 45
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
Epoch Screening Run In Treatment Period 1 Treatment Period 2
Visit Name Screening Baseline/Run -in Treatment Washout Treatment
Visit Numbers11 101 102 199 201 202 203 204 205 206 207 299 301 302 303
Study Day(s) -28 to -4 -3 -2 -1 1 2 3 4 5 6 7 8 9 10 11
Time (post -dose) - - - Predose: 0 H 0.5h 2h 4h - - Predose: 0 H 2h 4h - - - - - - - Predose: 0 H 2h 4h
Subjects domiciled Domiciled
Study completion 
information
Comments As Required
Safety Follow up Call

Novartis Confidential Page 46
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
Epoch Treatment Period 2 Treatment Period 3 End of Study
Visit Name Washout Treatment Washout EOS
Visit Numbers1304 305 306 307 399 401 402 403 404 499 599
Study Day(s) 12 13 14 15 16 17 18 19 20 21 22
Time (post -dose) - - - - - - - Predose: 0 H 2h 4h - - -
Informed consent
Inclusion / Exclusion criteria
Medical history/current medical 
conditions
Demography
Physical Examination S S
Hepatitis and HIV Screen
Alcohol Test, Drug Screen, and 
Cotinine Test
Electrocardiogram (ECG) X X
Pregnancy test X
Vital Signs5X X
Body W eight X X
Body Height
Hematology X X
Clinical Chemistry X X
Urinalysis X X
24 hour stool collection9X X
Bowel movements10X X X X X X X X X
Meal11X X X

Novartis Confidential Page 47
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
Epoch Treatment Period 2 Treatment Period 3 End of Study
Visit Name Washout Treatment Washout EOS
Visit Numbers1304 305 306 307 399 401 402 403 404 499 599
Study Day(s) 12 13 14 15 16 17 18 19 20 21 22
Time (post -dose) - - - - - - - Predose: 0 H 2h 4h - - -
Supplements13X X X
Dose administration14X X X
Concomitant medications X
Serious Adverse Events As Required
Adverse Events As Required
Subjects domiciled Domiciled X Domiciled X X X
Study completion information X
Comments As Required
Safety Follow up Call X19

Novartis Confidential Page 48
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
S –to be collected only as Source data
1Visit structure given for internal programming purpose only
2Review of inclusion and exclusion criteria and current medical conditions is required before baseline evaluation
3Serum pregnancy test at Screening and EOS
4Urine pregnancy test
5pulse, bloo d pressure, temperature
 
 
924-hour Stool collection:  stool pH, 
10To collect time, mass, and symptoms such as urgency, bloating; the Bristol Stool Chart will be use d to document the consistency of the stool at each bowel movement
11PART A: Standardized breakfast meal contains 600 calories of either 50% CHO, 15% Protein, 35% Fat OR 25% CHO, 40% Protein, 35 % Fat OR 0% CHO, 65% 
Protein, 35% Fat; all breakfast meals wil l be taken immediately after dosing with 50 mg LIK066 once daily
12Standardized breakfast meal to be given Day -1 through Day -3 (600 calories: 50% CHO; 15% Protein, 35% fat).
13PART B: All standardized breakfast meals (600 calories) will contain 50% CHO, 15% Protein, an d 35% Fat and will be given immediately after LIK066 50 mg qd; the 
supplements given include either Psyllium 6 grams qd OR calcium carbonate 1 gram to be provided in a 4mL sugar free liquid formula tion
1450 mg LIK066 
 
 
 
 
19A follow up call is required 30 days after EOS to check for SAEs 

Novartis Confidential Page 49
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
Details for highly  repetitive assessments

Novartis Confidential Page 50
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203

Novartis Confidential Page 51
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203

Novartis Confidential Page 52
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
8.2 Informed consent procedures
Eligible subjects may only be included in the study  after providing written (witnessed, where 
required b y law or regulation), I RB/IEC -approved informed consent.
Novartis will review the Investigators proposed informed consent form to ensure it complies 
with the ICHE6 GCP guideline and regulatory  requirements and is considered appropriate for 
this study . Any further changes to the proposed consent form suggested by the investigator 
must be agreed to b y Novartis before submission to the I RB/IEC.
Information about common side effects alread y known about the investigational drug can be 
found in the Investigator's Brochure (IB). This information will be included in the subject 
informed 
consent and should be discussed with the subject during the study  as needed. 
Any new information regarding the safet y profile of the investigational drug that is identified 
between IB updates will be communicated as appro priate, for example, via an Investigator 
Notification or an Aggregate Safet y Finding. New information might require an update to the 
informed consent and then must be discussed with the subject.
Ensure subjects are informed of the contraception requirement s outlined in the Section 4.2
(Exclusion criteria) and in Section 5.1 (Contraception requirements).
 
 
 
 
A copy  of the approved version of all consent forms must be provided to the Novartis monitor 
after IRB/IEC approval.
8.3 Subject screening
In general it is permissible to re-screen a subject if s/he fails the initial screening; however, 
each case must be discussed and agreed with the Sponsor on a case -by-case basis.
Information on what data should be collected for screening failures is outlined in the 
SiteOperations Manual.
8.4 Subject demographics/other baseline characteristics
Subject demographic and baseline characteristic data will be collected on all subjects.
Relevant medical history /current medical conditio ns data includes data until signature of 
informed consent. Where possible, diagnoses should be recorded rather than sy mptoms.
Subjects will be tested for substances of abuse (e.g., alcohol, amphetamines, barbiturates, 
benzodiazepines, cannabinoids, cocaine , and opiates), hepatitis B and C and HIV as noted in 
Table 8-1(Assessment Schedule) . Results will be available as Source data and will not be 
recorded within the eCRF. 

Novartis Confidential Page 53
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
Investigators have the discretion to record abnormal test findings on the medical history  CRF 
whenever in their judgment, the test abnormality  occurred prior to the informed consent 
signature. 
8.5 Efficacy  / Pharmacody namics
Diarrhea is the primary endpoint in this study . PD parameters inclu ding glucose, insulin, 
glucagon and incretin hormones will be evaluated in all subjects. PD samples will be collected 
at the time points defined in the Assessment schedule, Section 8.1. Follow instructions 
outlined in the Site Operations Manual regarding sample collection, numbering, processing 
and shipment.
8.5.1 Patient -Reported Outcome
8.5.1.3 Bow el movements
All bowel movements in this study  will be captured in a stool diary  and CRF that will include 
timing, weight, and symptoms such as urgency, bloating, flatus, and abdominal pain. 
Inaddition, the Bristol Stool Chart will be used to assess the stool consistency  to determine 
the categorization of diarrhea.

Novartis Confidential Page 54
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
8.6 Safet y
Safet y assessments are specified below; methods for assessment and recording are specified in 
the Site Operations Manual, with the Assessment Schedule (Section 
8.1) detailing when each 
assessment is to be performed.
Clinically  relevant deviations of laboratory  test results occurring during or at completion of 
the study  must be reported and discussed with Novartis personnel. The results should be 
evaluated for criteria defining an adverse event and reported as such if the criteria are met. 
Repeated evaluations are mandatory  until normalization of the result(s) or until the change is 
no longer clinicall y relevant. In cas e of doubt, Novartis personnel should again be contacted.
8.6.1 Electrocardiogram (ECG)
Full details of all procedures relating to the ECG collection and reporting are contained in the 
Site Operations Manual.
PR interval, QRS duration, heart rate, RR interval, QT interval, QTc
The Fridericia QT correction formula (QTcF) must be used for clinical decisions.
As applicable, QTcF and QTcB may be calculated in-house. Unless auto-calculated by the 
ECG machine, the investigator must calculate QTcF at the Screening and/or Baseline visit(s) 
(as applicable) to assess eligibility .
Clinically  significant abnormalities must be reported in the AE CRF.
8.6.2 Vital Signs
Body temperature
Blood pressure (BP) s ystolic and diastolic
Pulse Rate
8.6.3 Hematology
Hemoglobin, hematocrit, red blood cell count, white blood cell count with differentials 
(e.g.,
neutrophils, basophils, eosinophils, monocytes, and lymphocy tes), erythrocy te 
sedimentation rate, and platelet count will be measured.
8.6.4 Physical Examination
See Site Operations Manual for details.

Novartis Confidential Page 55
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
8.6.5 Clinical Chemistry
Sodium, potassium, creatinine, BUN/urea, uric acid, chloride, albumin, calcium, alkaline 
phosphatase, total bilirubin, bicarbonate/HCO 3, LDH, GGT, AST, ALT, CK, glucose, total 
cholesterol, trigly cerides. If the total bilirubin concentr ation is increased above 1.5 times the 
upper limit of normal, direct and indirect reacting bilirubin should be differentiated.
8.6.6 Urinaly sis
Dipstick measurements for specific gravit y, ketones, albumin, protein, glucose and blood will 
be performed. Microscopy , WBC, RBC and sediments will also be assessed in case of an 
abnormal dipstick test.
8.6.7 Body Height
Height will be measured.
8.6.8 Body Weight
Body weight will be measured.
Body mass index (BMI) will be calculated as (Body weight (kg) / [Height (m)]2)

Novartis Confidential Page 56
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
9 Safety  monitoring
9.1 Adverse events
An adverse event (AE) is any untoward medical occurrence (i.e., any unfavorable and 
unintended sign [including abnormal laboratory  findings], sy mptom or disease) in a subject or 
clinical investigation subject after providing written informed consent for participation in the 
study  until the end of study  visit. Therefore, an AE may or may not be temporally  or causall y 
associated with the use of a medicinal (investig ational) product.
In addition, all reports of intentional misuse and abuse of the study  treatment are also 
considered an adverse event irrespective if a clinical event has occurred. See Section 9.5 for 
a
n overview of the reporting requirements.
The occurrence of adverse events must be sought by non-directive questioning of the subject 
at each visit during the study . Adverse events also may  be detected when they  are volunteered 
by the subject during or between visits or through physical examination finding, laboratory  
test finding, or other assessments.
Abnormal laboratory  values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:
they induce clinical signs or sy mptoms,
they are considered clinically
 significant,
they require therapy .

Novartis Confidential Page 57
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
Clinically  significant abnormal laboratory  values or test results should be identified through a 
review of values outside of normal ranges/clinically  notable ranges, significan t changes from 
baseline or the previous visit, or values which are considered to be non-typical in subjects
with underl ying disease. Investigators have the responsibility  for managing the safet y of 
individual subject and identify ing adverse events. Alert ranges for liver and kidney  related 
events are included in Appendix 1 and Appendix 2 , respectivel y.
Adverse events must be recorded on the Adverse Even ts CRF under the signs, symptoms or 
diagnosis associated with them, and accompanied by  the following information:
1.the severit y grade  
mild: usually  transient in nature and generally  not interfering with normal activities
moderate: sufficiently  discomforti ng to interfere with normal activities
severe: prevents normal activities
2.its relationship to the study  treatment  
Yes or
No
3.its duration (start and end dates) or if the event is ongoing an outcome of not 
recovered/not resolved must be reported.
4.whether it constitutes a SAE (see Section 9.2 for definition of SAE) and which seriousness 
criteria have been met  
5.
Action taken regarding investigational treatment.
All adverse events must be treated appropriately. Treatment may include one or more of 
the following: 
no action taken (e.g. further observation only )
investigational treatment dosage increased/reduced
investigational treatment interrupted/withdrawn
concom itant medication or non -drug therap y given
hospitalization/prolonged hospitalization (see Section 9.2 for definition of SAE)
6. its outcome (not recovered/not resolved; recovered/resolved; recovering/resolv ing, 
recovered/resolved with sequelae; fatal; or unknown). 
Information about common side effects alread y known about the investigational drug can be 
found in the Investigator's Brochure (IB).  Once an adverse event is detected, it must be 
followed until its resolution or until it is judged to be permanent, and assessment should be 
made at each visit (or more frequentl y, if necessary ) of any changes in severity , the suspected 
relationship to the investigational drug, the interventions required to treat it, and the outcome.
The investigator must also instruct each subject to report any new adverse event (beyond the 
protocol observation period) that the subject, or the subject’s personal physician, believes 
might reasonabl y be related to study  treatment. This information must be recorded in the 
investigator’s source documents; however, if the AE meets the criteria of an SAE, it must be 
reported to Novartis.

Novartis Confidential Page 58
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
9.2 Serious adverse event reporting
9.2.1 Definition of SA E
An SAE is defined as any adverse event (appearance of (or worsening of any pre-existing) 
undesirable sign(s), symptom(s) or medical conditions(s)) which meets any one of the 
following criteria:
is fatal or life -threatening
results in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect
requires inpatient hospitalization or prolongation of existing hospitalization, unless 
hospitalization is for: 
treatment on an emergency  outpatient basis for an event not fulfilling any  of the 
definitions of a SAE given above and not resu lting in hospital admission
social reasons and respite care in the absence of any  deterioration in the subject’s 
general condition
is medically  significant, e.g. defined as an event that jeopardizes the subject or may  
require medical or surgical intervention.
All malignant neoplasms will be assessed as serious under “medically  significant” if other 
seriousness criteria are not met.
Life-threatening in the context of a SAE refers to a reaction in which the subject was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically  might have 
caused death if it were more severe (see Annex I V, ICH-
E2D Guideline).
Medical and scientific judgment should be exercised in deciding whether other situations 
should be considered serious reactions, such as important medical events that might not be 
immediately  life threatening or result in death or hospitalization but might jeopardize the 
subject or might require intervention to prevent one of the other outcomes listed above. 
Examples of such events are intensive treatment in an emergency  room or at home for allergic 
bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization or 
development of dependency or abuse (see Annex IV, ICH-E2D Guideline).
Any suspected tra nsmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
All AEs (serious and non-serious) are captured on the CRF; SAEs also require individual 
reporting to Novartis Drug Safet y & Epidemiology (DS&E) as per Section 9.2.2 .
9.2.2 SAE reporting
To ensure subject safet y, every  SAE, regardless of causalit y, occurring after the subject has 
provided informed consent and until 30 days [after the last study  visit/ following the last 
administration of study  treatment if there are post-treatment follow -
up visits with no required 
procedures] must be reported to Novartis within 24 hours of learning of its occurrence as 
described below. Any SAEs experienced after this period should only be reported to Novartis 
if the investigator suspects a causal relationsh ip to study  treatment.

Novartis Confidential Page 59
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
Note: SAEs reported by subjects deemed to be screen failures must be reported to Novartis as 
outlined here with appropriate information also captured in the CRFs as specified in the 
SiteOperations Manual.
All follow -up information f or the SAE including information on complications, progression of 
the initial SAE and recurrent episodes must be reported as follow -up to the original episode 
within 24 hours of the investigator receiving the follow -up information. An SAE occurring at 
a different time interval or otherwise considered completely  unrelated to a previously  reported 
one must be reported separatel y as a new event.
Follow - up information provided must describe whether the even t has resolved or continues, 
ifand how it was treated, whether the blind was broken or not (if applicable) and whether the 
subject continued or withdrew from study  participation. Each re-occurrence, complication, or 
progression of the original event must be reported as a follow -up to that event regardless of 
when it occurs.
If the SAE is not previously  documented in the Investigator’s Brochure or Package Insert 
(new occurrence) and is thought to be related to the study  treatment a Drug Safet y and 
Epidemiology  Department associate may urgently  require further information from the 
investigator for Health Authority  reporting. Novartis may need to issue an Investigator 
Notification (IN) to inform all investigators involved in any study with the same study  
treatment that this SAE has been reported. Suspected Unexpected Serious Adverse Reactions 
(SUSARs) will be collected and reported to the competent authorities and relevant ethics 
committees in accordance with EU Guidance 2011/C 172/01 or as per national regulatory 
requirements in participating countries.
Follow the detailed instructions outlined in the Site Operations Manual regarding the 
submission process for repor ting SAEs to Novartis.   Note: SAEs must be reported to 
Novartis within 24 hours of the investigator learning of its occurrence/receiving follow -up 
information.
9.3 Liver safety  monitoring
To ensure subject safety  and enhance reliability  in determining the hepatotoxic potential of an 
investigational drug, a standardized process for identification, monitoring and evaluation of 
liver events has to be fo llowed.
Please refer to Table 15 -1-Appendix 1 for complete definitions of liver events.
Follow -up of liver events
Every  liver event defined in Table 1 5-1-Appendix 1 should be followed up by  the investigator 
or designated personnel at the trial site, as summarized below. Additional details on actions 
required in case of liver events are outlined in Table 15 -2-Appendix 1 . 
Repeating liver chemistry tests (ALT, AST, TBL, PT/I
NR, ALP and γGT) to confirm 
elevation within 48- 72 hours.  
These liver chemistry  repeats should be performed using the local laboratory used b y the 
site. Repeat laboratory  test resul ts must be reported as appropriate via an electronic data 
transfer (if applicable), or entered on the appropriate unscheduled local laboratory  CRF.   

Novartis Confidential Page 60
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
If the initial elevation is confirmed, close observation of the subject will be initiated, 
including cons ideration of treatment interruption if deemed appropriate.
Discontinuation of the investigational drug (refer to Section 7.2 (Discontinuation of study  
treatment), if appropriate
Hospitalization of the sub ject if appropriate
Causality  assessment of the liver event
Thorough follow -up of the liver event should include: 
Repeating liver chemistry tests two or three times weekl y. Testing should include 
ALT, AST, AL P, PT/INR, and gGT. If total bilirubin is eleva ted > 2 x ULN, 
fractionation into direct and indirect bilirubin is required. To rule out muscular origin 
of transaminase elevations, CPK should be measured along with liver chemistry  tests. 
Frequency  of retesting can decrease to once a week or less if abnormalities stabilize 
or the study  drug has been discontinued and the sub ject is asy mptomatic. 
Retesting should be continued up to resolution. 
Obtaining a more detailed history  of symptoms and prior or concurrent diseases.
Obtaining a history  of concomitant drug use (including nonprescription medications 
and herbal and dietary  supplement preparations), alcohol use, recreational drug use, 
and special diets.
Exclusion of underly ing liver disease, as specified in Table 15 -3.
Imaging such as abdominal US, CT or MRI , as appropriate
Obtaining a history  of exposure to environmental chemical agents.
Considering gastroenterology  or hepatology  consultations.
All follow -up information, and the procedures performed must be recorded as appropriate in 
the CRF.
9.4 Renal safety  monitoring
Renal events are defined as one of the following:
Confirmed (after ≥ 24h) increase in serum creatinine of ≥ 25 % compared to baseline 
during normal hy dration status, and deemed as a new onset renal events in subjects with 
reduced renal function at the discretion of investigator(s)
A doubling in the urinar y albumin- creatinine ratio (ACR) or urinary  protein -creatinine 
ratio (PCR).
New onset ( ≥1+) proteinuria or hematuria 
Every  renal laboratory  trigger or renal event must be followed up by the investigator or 
designated personnel at the trial site. Recommend ed follow -up assessments are listed in 
Section 16- Appendix 2 .

Novartis Confidential Page 61
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
9.5 Reporting Medication errors including misuse/abuse
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, patient/subject 
or consumer (EMA definition).
Misuse refers to situations where the medicinal product is intentionally  and inappropriatel y 
used not in accordance with the pro tocol.
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal 
product, which is accompanied by  harmful ph ysical or psy chological effects.
All study  treatment errors and uses outside of what is foreseen in the protocol will be 
collected in the dose administration record (DAR) CRF.  Study  treatment errors are only  to be 
reported to Novartis Drug Safet y and Epidemiology  department if the treatment error is 
associated with an SAE.
All instances of misuse or abuse must be documented in the adverse event (AE) CRF 
irrespective of the misuse/abuse being associated with an AE/SAE. In addition, all instances 
of misuse or abuse must be reported to Novartis Drug Safet y and Epidemiology . As such, 
instances of misuse or abuse are also tobe reported using the SAE form/CRF. Table 9-1
summarizes the reporting requirements.
Table 9
-1 Summary  of reporting req uirements for medication errors
Treatment error typeDocument in Dose 
Administration (DA R) CRFDocument in A E 
CRFComplete SA E 
form/CRF
Unintentional study 
treatment errorYes Only if associated 
with an AEOnly if associated with 
an SAE
Misuse/Abuse Yes YesYes, even if not 
associated with a SAE
For more information on AE and SAE definition and reporting requirements, 
please seeSection 9.1 and Section 9.2, respectively.
9.6 Pregnancy  reporting
To ensure subject safet y, each pregnancy  occurring after signing the informed consent must 
be reported to Novartis within 24 hours of learning of its occurrence. The pregnancy should 
be followed up to determine outcome, in cluding spontaneous or voluntary  termination, details 
of the birth, and the presence or absence of any birth defects, congenital abnormalities, or 
maternal and/or newborn complications.
Pregnancy  must be recorded on the Pharmacovigilance Pregnancy  Form andreported by the 
investigator to the local Novartis Drug Safet y and Epidemiology  Department. 
Pregnancy follow -
up should be recorded on the same form and should include an assessment 
of the possible relationship to the study  treatment.
Any SAE experienced during the pregnancy  and unrelated to the pregnancy  must be reported 
on a SAE form.

Novartis Confidential Page 62
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
The study  drug must be discontinued, though the subject may stay in the study , if she wishes 
to do so. All assessments that are considered as a risk during pregnancy  must not be 
performed. The subject may  continue all other protocol assessments.
Pregnancy  outcomes should be collected for the female partners of any males who took study 
treatment in this study . Consent to report information regarding these pregnancy  outcomes 
should be obtained from the mother. 
9.7 Early phase safety  monitoring
The Investigator will monitor adverse events in an ongoing manner and inform the Sponsor of 
any clinically  relevant observations. Any required safety  reviews will be made jointly  between 
medi cally qualified personnel representing theSponsor and Investigator. Such evaluations may 
occur verbally , but the outcome and key discussion points will besummarized in writing (e-mail) 
and made available to both Sponsor and all Investigator(s). Criteria pertaining to stopping the 
study /treatment or adapting the study  design are presented above.
9.8 Monitoring hy poglycemia
Because hypoglycemia is a potential risk of LIK066 treatment, glucose levels will be 
measured when a subject experiences a clinicall y symptomatic hypogly cemia. If a confirmed 
glucose 
level is <56 mg/dL  by repeated measurement, study  treatment will be discontinued 
and the patient will be treated by the clinical staff according to standard of care for 
hypoglycemia.
During the course of the study, if any patient experiences symptoms of hypoglycemia 
(shakiness, nervousness, hunger, nausea, palpitations, dizziness, orconfusion), they will be 
instructed to seek immediate medical evaluation and treatment.  
9.9 Monitoring orthostatic hy potension
Because orthostatic hypotension is a potential risk of LIK066 treatment, orthostatic blood 
pressure readings will be recorded throughout the study  as shown in the Assessment schedule .
Any patient with clinically significant symptomatic orthostasis (more than 20 mmHg drop in 
systolic or 10 mmHg drop in diastolic blood pressure and increase in heart rate >20bpm) will 
have the study  treatment placed on hold. In addition, individuals with orthostasis will be 
treated with volume replacement accordin g to standard of care (refer toSection
7.2
(Discontinuation of study treatment) .
9.10 Monitoring ketoacidosis
In rare cases, SGLT -2 inhibitors can lead to ketoacidosis. Therefore, investigators must pay 
close attention for any  signs of ketoacidosis. Signs and sy mptoms of ketoacidosis may  include 
deep and rapid breathing, nausea, vomiting, severe abdominal pain, co nfusion, unusual fatigue 
or sleepiness, and coma. All signs and/or symptoms and results from relevant laboratory  tests 
must be reported on the AE eCRF. If ketoacidosis is confirmed, the study  treatment should be 
discontinued as per Section 7.2 (Discontinuation of study  treatment) and appropriate measures 
must be taken to correct the acidosis and monitor glucose levels according to standard of care.

Novartis Confidential Page 63
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
Every  case of ketoacidosis must be reported to the Ketoaci dosis Adjudication Committee 
(seeSection 10.5).
10 Data revie w and database management
10.1 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a Novartis 
representative will review the protocol and CRFs with the invest igators and their staff. 
During the study  Novartis employ s several methods of ensuring protocol and GCP 
compliance and the quality /integrit y of the sites’ data. The monitor will visit the siteto check 
the completeness of subject records, the accuracy  of entries on the CRFs, the adherence to the 
protocol and to Good Clinical Practice, the progress of enrollment, and ensure that study  drug 
is being stored, dispensed, and accounted for according to specifications. Key  study  personnel 
must be available to assist the monitor during these visits.
The investigator must maintain source documents for each subject 
in the study , consisting of 
case and visit notes (hospital or clinic medical records) conta ining demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information on CRFs must be traceable to these source documents in the 
subject's file. The investigator must also keep the original informed consent form signed by 
the subject (a signed copy  is given to the subject).
The investigator must give the monitor access to all relevant source documents to confirm 
their consistency  with the CRF entries. Novartis monitoring standards require full verification 
for the presence of informed consent, adherence to the eligibility  criteria, documentation of 
SAEs, and the recording of data that will be used for all primary  and safet y variables. 
Additional checks of the consistency  of the source data with the CRFs are performed 
according to the study -specific monitoring plan. No information in source documents about 
the identity  of the subjects will be disclosed.
10.2 Data collection
Designated investigator staff will enter the data required by the protocol into the Electronic 
Case Report Forms using fully validated software that conforms to 21 CFR Part 11 
requirements. Designated investigator site staff will not be given access to the EDC system 
until they  have been trained. Automatic validation pro grams check for data discrepancies and, 
by generating appropriate error messages, allow the data to be confirmed or corrected before 
transfer of the data to Novartis or the CRO working on behalf of Novartis. The Investigator 
must certify  that the data entered into the Electronic Case Report Forms are complete and 
accurate. After database lock, the investigator will receive copies of the subject data for 
archiving at the investigational site.
Data not requiring a separate written record will be defined in the Site Operations Manual and 
Assessment schedule and can be recorded directly  on the CRFs. All other data captured for 
this study  will have an external originating source (either written or electronic) with the CRF 
not being considered as source.

Novartis Confidential Page 64
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
All data should be recorded, handled and stored in a way that allows its accurate reporting, 
interpretation and verification.
10.3 Database management and quality  control
Novartis staff or CRO working on behalf of Nova rtis review the data entered into the CRFs by 
investigational staff for completeness and accuracy  and instruct the site personnel to make any 
required corrections or additions. Queries are sent to the investigational site using an 
electronic data query . Designated investigator site staff is required to respond to the query  and 
confirm or correct the data. If the electronic query  system is not used, a paper Data Query 
Form will be faxed to the site. Site personnel will complete and sign the faxed copy  and fa x it 
back to Novartis staff or CRO working on behalf of Novartis who will make the correction to 
the database. The signed copy  of the Data Query  Form is kept at the investigator site.
Concomitant medications entered into the database will be coded using the WHO Drug 
Reference List, which employ s the Anatomical Therapeutic Chemical classification system. 
Medical history /current medical conditions and adverse events will be coded using the 
Medical dictionary  for regulatory  activities (MedDRA) terminology .
Laboratory  samples will be processed centrall y and the results will be sent electronically  to 
Novartis (or a designated CRO).
ECG readings will be processed locall y and the results will be sent electronically  to Novartis 
(or a designated CRO).
The occurrence of any protocol deviations will be determined. After these actions have been 
completed and the database has been declared to be complete and accurate, it will be locked 
and the treatment codes will be unblinded and made available for data analy sis. Any changes 
to the database after that time can only be made by joint written agreement between the 
COAR Analy tics NIBR Franchise Head and the relevant NIBR TA Head.
10.4 Data Monitoring Committee
Not applicable.
10.5 Adjudication Committee
An Adj udication Committee for monitoring ketoacidosis will be established to assess 
suspected cases of ketoacidosis as described in the SOM.

Novartis Confidential Page 65
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
11 Data analy sis
All data anal yses will be performed by  study  part. 
11.1 Analysis sets
For all anal ysis sets, subjects will be anal yzed according to the stud y treatment(s) received.
The safety  anal ysis set will include all subjects that received any  study  drug.
 
 
The PD analysis set will include all subjects with available PD data and no protocol 
deviations with relevant impact on PD data.
11.2 Subject demographics and other baseline characteristics
All data for background and demographic variables will be listed by treatment sequence and 
subject. Summary  statistics will be provided for all subjects, as well as for each treatment 
sequence.
Relevant medical history, current medical conditions, results of laboratory screens, drug tests 
and an y other relevant information will be listed by treatment sequence and subject.
11.3 Treatments
Data for study  drug administration and concomitant therapies will be listed by treatment 
sequence and subject.
11.4 Analysis of the primary  variable(s)
11.4.1 Variable(s)
The primary  endpoint will be the number of episodes of diarrhea per day.  It is defined as the 
total number of stools with a BSC score of 6 or 7 per day .
11.4.2 Statistical model, hypothesis, and method of analy sis
The primary  analysis will be performed by study part. The daily  number of diarrhea will be 
analyzed using a negative binomial mixed effects model with fixed effects of period, 
treatment, day, the period -by-day interaction, and the treatment -by-day interaction, and a 
random subject effect. An unstructured covariance matrix will be specified for the repeated 
observations on a subject within the same period. The least-squares mean and associated 80% 
CI for the number of diarrhea episodes per day for each treatment, and the estimated mean 
difference between each treatment, the p-value, and corresponding two-sided 80% CI, will be 
extracted from the model for each day, and summarized by a table and a line chart. 
Conclusions from the analy sis will be based on treatment differences from all 3 days, 
collectivel y.

Novartis Confidential Page 66
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
11.4.3 Handling of missing values/censoring/discontinuations
The primary  analysis will be performed on all available data. There will be no imputation of 
missing data. 
11.4.4 Sensitivity analy ses
As a sensitivity  analysis, the interaction between treatment and day will be assessed, and if 
non-significant, the results from the 3 days will be averaged and corresponding model -based 
quantities extracted. 
Covariates such as baseline number of diarrhea may be included in the model when 
appropriate . 
The model assumption of negative binomial distribution will be examined, especiall y if over-
dispersion (i.e. variance>mean) exists. If the data doesn’t fit negative binomial distribution or 
over-dispersion doesn’t
exist, other models such as Poisson regression will be explored.  
The model assumption of no first-order carry -over effect may be evaluated by incorporating 
first-order carry -over effects into the above statistical model, and performing a type 3 test for
the first -order carry -over effect. 
11.5 Analysis of secondary  variable(s)
11.5.1 Efficacy  / Pharmacodynamics
The three -day total number of episodes of diarrhea per period will be summarized by 
treatment, and analyzed using a negative binomial model with fixed effect s of subject, period 
and diet.  The least-squares mean and associated 80% CI for the three -day total number of 
diarrhea episodes per period for each treatment, and the estimated mean difference between 
each treatment, the p-value, and corresponding two-sided 80% CI, will be extracted from the 
model, and summarized by  a table and a line chart.
The model assumption of no first-order carry -over effect and the negative -binomial 
distribution may  be evaluated in a similar fashion as the primary  endpoint. 
Other secondary  endpoints include average consistency  with Bristol stool chart, average stool 
pH, average stool weight over each 24
hour collection period. They  willbe summarized by 
treatment, and analyzed by a
 linear mixed model with fixed effects of subject, period, 
treatment, and baseline measurement.  Theleast-squares mean and associated 80% CI for 
each treatment, and the estimated mean difference 
between each treatment, the p-value, and 
corresponding two
-sided 80% CI, will be extracted from the model, and summarized by a 
table and a line chart.

Novartis Confidential Page 67
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
11.5.2 Safety
Vital signs
All vital signs data will be listed by treatment sequence, subject, and visit/time and if ranges 
are available abnormalities (and relevant orthostatic changes) will be flagged. 
Summary statistics for both observed values and change from baseline will be provided by 
treatment and visit.
ECG evaluations
All ECG data will be listed by treatment sequence, subject and visit/time, abnormalities will 
be flagged. Summary  statistics for both observed values and change from baseline will be 
provided b y treatment and visit.
Clinical laboratory  evaluations
All laboratory  data will be listed by treatment sequence, subject, and visit/time and if normal 
ranges are available abnormalities will be flagged. Summary  statistics will be provided by 
treatment and visit.
Adverse events
All information obtained on adverse events will be display ed by treatment sequence and 
subject.
The number and percentage of subjects with adverse events will be tabulated by body system 
and preferred term with a breakdown by treatment. An adverse event starting in one 
period/epoch and continuing into the next period/epoch is coun ted only in the onset period. 
Asubject with multiple adverse events within a body  system and treatment period/epoc h is 
only counted once towards the total of this body  system and treatment.
Other safety  evaluations
Immunogenicity
Not a pplicable.
11.5.3 Pharmacokinetic / pharmacodynamic interactions
Not a pplicable.
11.5.4 Other assessments
Not a pplicable.

Novartis Confidential Page 68
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203

Novartis Confidential Page 69
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
11.7 Sample size calculation
The sample size justification for this study  is based on internal data from Part 2 of the LIK066 
obesity  PoC study  (LIK066X2201) on the 50 mg tid treatment regimen.
For patients on the 50 mg tid regimen, a mean (range) of 3.5 (0-12), 4.8 (0-18), and 3.9 (0 -18) 
daily  episodes of diarrhea were observed for Days 1, 2 and 3, respectivel y, of which 
3.2episodes occurred between the 1st and 2nd dose on Day 1. If the true effect of the low 
carb diet or of the supplements is a reduction in the number of episodes per day from a mean 
of 3 episodes per day on the high carb diet to 1.5 episodes per day, or from a mean of 
5episodes per day  to 3 per day , then 5 subjects per sequence per study  part (30 subjects total) 
with complete data will provide 80% power to detect the reduction. Assuming a drop-out rate 
of 37.5%, 8 subjects per sequence (48 total subjects) should be enrolled. 

Novartis Confidential Page 70
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
These results are based on 1000 simulated trials. For each simulated trial, the number of daily 
diarrhea episodes was generat ed from a Poisson distribution, where period- specific means, 
adjusted by the treatment effect, share a common gamma -distributed random subject effect in 
order to reflect a correlation between observations from the same subject. Only a single 
observation per-period for each subject was generated, reflecting one day of treatment. 
Each trial was analy zed using the GLIMMIX procedure in SAS, using a negative binomial 
model with fixed effects of treatment and period and normally  distributed random subject 
effects , and assuming no carry over effects from one period to the next.
Two plausible scenarios for the variabilit y of the number of daily diarrhea episodes were 
considered: (1) assuming the variabilit y is as was observed in LIK066X2201, reflected by a 
dispersion parameter in the negative binomial model of 2.4, and (2) assuming the endpoint is 
less variable, reflected by a dispersion parameter of 1. In both scenarios, the power for 
detecting the reductions is at least 80%. Simulations were also performed under two
additional scenarios where non-zero period effects were assumed (a sequential 
increase/decrease of 0.1 in the log scale), and these also demonstrated 
sufficient power with
5 completers per sequence.
11.8 Power for analy sis of key secondary  variables
Power for key secondary  variables doesn’t apply  since there will be no formal hypothesis 
testing for the secondary  variables. 
11.9 Interim analy ses
Refer to Section 3.5.
12 Ethical considerations
12.1 Regulatory  and ethical compliance
This clinical study  was designed and shall be implemented, executed and reported in 
accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with 
applicable local regulations (including European Directive 2001/20/EC, US Code of Federal 
Regulations Title 21, and Japanese Ministry  of Health, Labor, and Welfare), and with the 
ethical principles laid down in the Declaration of Helsinki.
12.2 Responsibilities of the investigator and IRB/IEC
Before initiating a trial, the investigator/institution must obtain approval/favorable opinion 
from the Institutional Review Board/Independent Ethics Committee (IRB/IEC) for the trial 
protocol, written informed consent form, consent form updates, subject recruitment 
procedures (e.g. advertisements) and any other written information to be provided to subjects. 
Prior to study  start, the investigator is required to sign a protocol signature page confirming 
his/her agreement to conduct the study  in accordance with these documents and all of the 
instructions and procedures found in this protocol and to give access to all relevant data and 
records to Novartis monitors, auditors, Novartis Quality  Assurance representatives, designated 
agents of Novartis, IRBs/IECs, and regulatory  authorities as required. If an inspection of the 

Novartis Confidential Page 71
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
clinical site is requested by a regulatory  authority , the investigator must inform Novartis 
immediately  that this request has been made.
For multi- center trials, a Coordinating Investigator will be selected by Novartis around the 
time of Last Patient Last Visit to be a reviewer and signatory  for the clinical study  report. 
12.3 Publication of study  protocol and results
The key design elements of this protocol will be posted in a publicly  accessible database such 
as clinicaltrials.gov. In addition, upon study  completion and finalization of the study  report 
the results of this trial will be either submitted for publication and/or posted in a publicl y 
accessible database of clinical trial results.
13 Proto col adherence
This protocol defines the study  objectives, the study  procedures and the data to be collected 
on study  participants. Additional assessments required to ensure safet y of subjects should be 
administered as deemed necessary  on a case by case basis. Under no circumstances is an 
investigator allowed to collect additional data or conduct any additional procedures for any 
research related purpose involving an y investigational drugs under the protocol.
Investigators ascertain they will apply due diligence to avoid protocol deviations. If an 
investigator feels a protocol deviation would improve the conduct of the study  this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by Novartis 
and approved by the IRB/IEC and health authorities, where required, it cannot be 
implemented.
13.1 Protocol A mendments
Any change to the protocol can only be made in a written protocol amendment that must be 
approved by Novartis, Health Authorities where required, and the IRB/IEC prior to 
imple mentation.
Amendments that are intended to eliminate an apparent immediate hazard to subjects may be 
implemented immediately , provided the Health Authorities are subsequently  notified by 
protocol amendment and the reviewing IRB/IEC is notified.
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any immediate action required for the safety  of any subject included in this 
study , even if this action represents a deviation from the protocol. In such cases, the reporting 
requirements identified in Section 9 (Safet y Monitoring) must be followed and the Study  Lead 
informed.

Novartis Confidential Page 72
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
14 References
Abdul -Ghani MA, Norton L , DeFronzo RA (2015) Renal sodium -glucose cotransporter 
inhibition in the management of ty pe 2 diabetes mellitus. Am. J. Phy siol. Renal Phy siol. p. 
F889 -900.
Chao EC, Henry  RR (2010) SGL T2 inhibition –a novel strategy  for diabetes treatment. Nat 
Rev Drug Discov. p. 553. 
Macha S, Mattheus M, Halabi A, et al (2 014) Pharmacokinetics, pharmacody namics and 
safet y of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with 
renal impairment. Diabetes Obes Metab p. 215 -22.
Martín MG, Turk E, Lostao MP, et al (1996) Defects in Na+/glucose cot ransporter (SGLT1) 
trafficking and function cause glucose -galactose malabsorption. Nat. Genet. p. 216-20.
Morgen CS, Sørensen TI (2014) Obesit y: global trends in the prevalence of overweight and 
obesity . Nat Rev Endocrinol p. 513-4.
Pfister M, Whaley  JM, Z hang L, et al (2011) Inhibition of SGL T2: a novel strategy  for 
treatment of t ype 2 diabetes mellitus. Clin. Pharmacol. Ther. p. 621 -5.
Turk E, Zabel B, Mundlos S, et al (1991) Glucose/galactose malabsorption caused b y a defect 
in the Na+/glucose cotranspor ter. Nature p. 354 -6.
U.S Department of Health and Human Services and U.S Department of Agriculture. 2015 –
2020 Dietary  Guidelines for Americans. 8thEdition. December 2015. 

Novartis Confidential Page 73
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
15 Appendix 1: Liver Event Definitions and Follo w-up 
Requirements
Table 15-1 Liver Event Definitions
Definition Thresholds
Potential Hy’s law cases ALT or AST > 3 × ULN and TBL > 2 × ULN without initial increase 
in ALP to > 2 × ULN
ALT or AST elevation with 
coagulopathyALT or AST > 3 × ULN and INR > 1.5 (in the absence of 
anticoagulation)
ALT or AST elevation 
accompanied by sy mptomsALT or AST > 3 × ULN accompanied by (general) malaise, 
fatigue, abdominal pain, nausea, or vomiting, or rash, or 
eosinophilia
Isolated ALT or AST elevation ALT or AST > 8 × ULN
5 x ULN < ALT/AST £ 8 x ULN
3 x ULN < ALT/AST £ 5 x ULN
Isolated ALP elevation ALP > 2 × ULN (in the absence of known bone pathology)
OthersAny clinical event of jaundice (or equivalent term)
Any adverse event potentially indicative of liver toxicity

Novartis Confidential Page 74
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
Table 15-2 Actions required for Liver Events
Criteria Actions required
Potential Hy’s Law case
Discontinue the study treatment immediately
Hospitalize, if clinically appropriate
Establish causality
Complete CRFs per liver event guidanceALT or AST elevation with coagulopathy
ALT or AST elevation accompanied by 
symptoms
Isolated ALT or AST elevation > 8 × ULN
Jaundice
Isolated ALT or AST elevation > 5 to 
≤ 8× ULNIf confirmed, consider interruption or discontinuation of 
study drug
If elevation persists for more than 2 weeks, 
discontinue the study drug
Establish causality
Complete CRFs per liver event guidance
Isolated ALT or AST elevation > 3 to 
≤ 5× ULN (patient is asy mptomatic)Monitor liver chemistry tests two or three times weekly
Isolated ALP elevation Repeat liver chemistry  tests within 48 -72 hours
If elevation is confirmed, measure fractionated ALP; 
if >50% is of liver origin, establish hepatic causality
Complete CRFs per liver event guidance
Any AE potentially indicative of liver 
toxicityConsider study treatment interruption or 
discontinuation
Hospitalize if clinically appropriate
Complete CRFs per liver event guidance
Table 15-3 Exclusion of underly ing liver disease
Disease Assessment
Hepatitis A, B, C, E IgM anti -HAV; HBSAg, IgM anti-HBc, HBV DNA; anti -HCV, 
HCV RNA, IgM & IgG anti -HEV, HEV RNA
CMV, HSV, EBV infection IgM & IgG anti -CMV, IgM & IgG anti -HSV; IgM & IgG anti -EBV
Autoimmune hepatitis ANA & ASMA titers, total IgM, IgG, IgE, IgA
Alcoholic hepatitis Ethanol history, gG T, MCV, CD -transferrin
Nonalcoholic steatohepatitis Ultrasound or MRI
Hypoxic/ischemic hepatopathy Medical histor y: acute or chronic CHF, hypotension, hypoxia, 
hepatic venous occlusion. Ultrasound or MRI.
Biliar y tract disease Ultrasound or MRI, ERCP as appropriate.
Wilson disease Caeruloplasmin
Hemochromatosis Ferritin, transferrin
Alpha -1-antitr ypsin deficiency Alpha -1-antitr ypsin

Novartis Confidential Page 75
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
16 Appendix 2: Specific Renal A lert Criteria and A ctions
Table 16-1 Specific Renal A lert Criteria and A ctions
Criteria Action required
Serum creatinine (sCr) increase
25 –49% compared to baselineConsider causes and possible interventions
Follow up within 2 -5 day s
Serum creatinine increase >50% Consider causes and possible interventions
Repeat assessment within 24 -48h if possible
Consider drug interruption or discontinuation 
unless other causes are diagnosed and 
corrected
Consider hospitalization and specialized 
treatment
Protein -creatinine or albumin -creatinine ratio 
increase ≥ 2 -fold
or
new onset dipstick proteinuria ≥ 1+
or
Albumin -creatinine ratio (ACR) ≥ 30 mg/g or 
≥3 mg/mmol;
or
Protein -creatinine ratio (PCR ) ≥ 150 mg/g 
or >15 mg/mmolConsider causes and possible interventions
Assess serum albumin & serum protein
Repeat assessment to confirm
Consider drug interruption or discontinuation 
unless other causes are diagnosed and 
corrected
New onset glucosuria on urine dipstick (unless 
related to concomitant tr eatment, diabetes)Assess & document:
Blood glucose (fasting)
Serum creatinine
Urine albumin -creatinine ratio
New hematuria on dipstickAssess & document :
Urine sediment microscopy
Assess sCr and urine albumin- creatinine ratio
Exclude infection, trauma, bleeding from the 
distal urinary tract/bladder, menstruation
Consider bleeding disorder
Additional specialized assessments are available to assess renal function or renal pathology . 
(Note: In exceptional cases when a nephrologist considers a renal biopsy ,it is strongl y 
recommended to make specimen slides available for evaluation by Novartis to potentiall y 
identify  project -wide patterns of nephrotoxicity .)

Novartis Confidential Page 76
Amended Protocol Version v01 (Clean ) Protocol No. CLIK066B2203
Whenever a renal event is identified, a detailed subject history  and examination are indicated 
to ide ntify , document and potentiall y eliminate risk factors that may have initiated or 
contributed to the event:
Blood pressure assessment (after 5 min rest, with an appropriate cuff size)
Signs and s ymptoms such as fever, headache, shortness of breath, back or abdominal pain, 
dysuria, hematuria, dependent or periorbital edema
Changes in blood pressure, body  weight, fluid intake, voiding pattern, or urine output
Concomitant events or procedures such as trauma, surgical procedures, cardiac or hepatic 
failure, contrast media or other known nephrotoxin administration, or other potential 
causes of renal d ysfunction, e.g., dehy dration, hemorrhage, tumor l ysis
Table 16-2 Follo w-up of ren al events
Action Follow up
Assess *, document and record in the Case 
Report Form (CRF) or via electronic data load. 
Review and record possible contributing factors 
to the renal event (co -medications, other co -
morbid conditions) and additional diagnostic 
procedures (MRI etc) in the CRF.Urine dipstick and sediment microscopy
Blood pressure and body weight
Serum creatinine, electrolytes (sodium, 
potassium, phosphate, calcium), bicarbonate 
and uric acid
Urine output
Monitor subject regularly (frequency at 
investigator’s discretion) until:Event resolution: (sCr within 10% of baseline or 
protein -creatinine ratio within 50% of baseline)
or
Event stabilization: sCr level with ±10% 
variability over last 6 months or protein -
creatinine ratio stabilization at a ne w level with 
±50% variability over last 6 months.
* Urine osmolality : in the absence of diuretics or chronic kidney  disease this can be a very 
sensitive metric for integrated kidney  function that requires excellent tubular function. A high 
urinary  osmolal ity in the setting of an increase in sCr will point toward a “pre-renal” cause 
rather than tubular toxicity.
